

Ticker: 6491

**PEGAVISION CORPORATION AND SUBSIDIARIES
CONSOLIDATED FINANCIAL STATEMENTS
WITH REVIEW REPORT OF INDEPENDENT AUDITORS
AS OF SEPTEMBER 30, 2025 AND 2024
AND FOR THE NINE-MONTH PERIODS THEN ENDED**

Address: No.5 Shing Yeh Street, GuiShan District, Taoyuan City, Taiwan 33341
Telephone: (03)329-8808

The reader is advised that these consolidated financial statements have been prepared originally in Chinese. In the event of a conflict between these financial statements and the original Chinese version or difference in interpretation between the two versions, the Chinese language financial statements shall prevail.

**Consolidated Financial Statements
Index**

Item	Page
1. Cover sheet	1
2. Index	2
3. Independent Auditors' Review Report	3-4
4. Consolidated balance sheets	5-6
5. Consolidated statements of comprehensive incomes	7
6. Consolidated statements of changes in equity	8
7. Consolidated statements of cash flows	9
8. Footnotes to the consolidated financial statements	
(1) History and organization	10
(2) Date and procedures of authorization of financial statements for issue	10
(3) Newly issued or revised standards and interpretations	10-15
(4) Summary of significant accounting policies	15-20
(5) Significant accounting judgments, estimates and assumptions	21
(6) Contents of significant accounts	21-53
(7) Related party transactions	53-57
(8) Assets pledged as collateral	58
(9) Significant contingencies and unrecognized contract commitments	58
(10) Losses due to major disasters	58
(11) Significant subsequent events	58
(12) Others	59-71
(13) Other disclosures	
1. Information on significant transactions	71
2. Information on investees	72
3. Information on investments in Mainland China	73-76
(14) Segment information	76

REVIEW REPORT OF INDEPENDENT ACCOUNTANTS

To : the Board of Directors and Shareholders of
Pegavision Corporation

Introduction

We have reviewed the accompanying consolidated balance sheets of Pegavision Corporation (the “Company”) and its subsidiaries as of September 30, 2025 and 2024, the related consolidated statements of comprehensive income for the three-month and nine-month periods then ended, the related consolidated statements of changes in equity and cash flows for the nine-month periods then ended, and notes to the consolidated financial statements, including the summary of significant accounting policies (together “the consolidated financial statements”). Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” as endorsed and became effective by Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on these consolidated financial statements based on our reviews.

Scope of Review

We conducted our reviews in accordance with the Standards on Review Engagement 2410, “Review of Financial Information Performed by the Independent Auditor of the Entity” of the Republic of China. A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing of the Republic of China and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Conclusion

Based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of the Company and its subsidiaries as of September 30, 2025 and 2024, and their consolidated financial performance for the three-month and nine-month periods then ended and cash flows for the nine-month periods then ended, in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” as endorsed and became effective by Financial Supervisory Commission of the Republic of China.

/s/Chang, Chih-Ming

/s/Chen, Kuo-Shuai

Ernst & Young
Taiwan, R.O.C.
October 27th, 2025

Notice to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, results of operations and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China on Taiwan and not those of any other jurisdictions. The standards, procedures and practice to review such consolidated financial statements are those generally accepted and applied in the Republic of China on Taiwan.

Accordingly, the accompanying consolidated financial statements and report of independent accountants are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice. As the financial statements are the responsibility of the management, Ernst & Young cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

Pegavision Corporation and Subsidiaries
Consolidated Balance Sheets
As of September 30, 2025, December 31, 2024 and September 30, 2024
(Amounts Expressed In Thousands of New Taiwan Dollars)

Assets			As of September 30, 2025		As of December 31, 2024		As of September 30, 2024	
Code	Accounts	Notes	Amount	%	Amount	%	Amount	%
11xx	Current assets							
1100	Cash and cash equivalents	6(1)	\$1,654,282	10	\$2,002,176	14	\$1,610,163	11
1110	Financial assets at fair value through profit or loss	6(2)	922,565	6	1,121,378	8	1,578,104	11
1136	Financial assets measured at amortized cost	6(4)	1,825,242	11	1,134,932	8	1,005,069	7
1170	Accounts receivable, net	6(5), 6(19)	1,066,792	7	806,188	5	787,648	5
1200	Other receivables	7	36,940	-	21,001	-	30,105	-
1220	Current tax assets		45	-	780	-	1,874	-
1310	Inventories, net	6(6)	790,205	5	671,023	5	781,185	5
1410	Prepayments		123,984	1	119,066	1	137,678	1
1470	Other current assets		78,415	1	40,980	-	76,912	1
	Total current assets		6,498,470	41	5,917,524	41	6,008,738	41
15xx	Non-current assets							
1517	Financial assets at fair value through other comprehensive income	6(3)	50,880	-	-	-	-	-
1535	Financial assets measured at amortized cost	6(4)	1,159	-	-	-	-	-
1550	Investment accounted for using equity method	6(7)	19,531	-	19,751	-	19,800	-
1600	Property, plant and equipment, net	6(8), 7, 8, 9	8,562,932	54	7,860,209	54	7,829,377	54
1755	Right-of-use assets, net	6(20)	335,223	2	370,874	2	376,458	3
1780	Intangible assets, net	6(9)	33,618	-	22,054	-	19,738	-
1840	Deferred tax assets	4, 6(24)	80,266	1	83,325	1	78,693	1
1900	Other non-current assets	6(8), 6(10), 8	360,839	2	272,026	2	175,053	1
	Total non-current assets		9,444,448	59	8,628,239	59	8,499,119	59
	Total Assets		\$15,942,918	100	\$14,545,763	100	\$14,507,857	100

(The accompanying notes are an integral part of the consolidated financial statements.)

Pegavision Corporation and Subsidiaries
Consolidated Balance Sheets (Continued)
As of September 30, 2025, December 31, 2024 and September 30, 2024
(Amounts Expressed In Thousands of New Taiwan Dollars)

Liabilities and Equity			As of September 30, 2025		As of December 31, 2024		As of September 30, 2024	
Code	Accounts	Notes	Amount	%	Amount	%	Amount	%
21xx	Current liabilities							
2100	Short-term borrowings	6(11)	\$880,429	6	\$351,503	3	\$668,544	5
2130	Contract liabilities	6(18), 7	68,715	-	55,329	-	106,666	1
2150	Notes payable		1,605	-	2,262	-	3,788	-
2170	Accounts payable		289,641	2	196,289	1	196,285	1
2200	Other payables	6(12), 7	2,130,712	13	1,684,261	12	1,832,730	13
2230	Current tax liabilities	4, 6(24)	220,473	1	118,311	1	42,037	-
2250	Provisions	4, 6(13)	3,600	-	-	-	-	-
2280	Lease liabilities	6(20)	34,731	-	31,533	-	32,736	-
2300	Other current liabilities	6(14), 6(15), 8	389,422	3	350,662	2	305,070	2
	Total current liabilities		4,019,328	25	2,790,150	19	3,187,856	22
25xx	Non-current liabilities							
2540	Non-current portion of long-term borrowings	6(15), 8	447,655	3	548,764	4	515,006	4
2570	Deferred tax liabilities	4, 6(24)	85,843	1	70,906	-	75,764	-
2580	Lease liabilities	6(20)	66,396	-	73,586	1	77,070	1
2645	Guarantee deposits received	7	3,646	-	3,615	-	3,400	-
2670	Other non-current liabilities	6(14)	48	-	47	-	59	-
	Total non-current liabilities		603,588	4	696,918	5	671,299	5
	Total liabilities		4,622,916	29	3,487,068	24	3,859,155	27
31xx	Equity Attributable to Shareholders of the Parent							
3100	Capital	6(17)						
3110	Common stock		780,000	5	780,000	5	780,000	5
3200	Capital surplus	6(17)	4,269,544	27	4,269,544	29	4,269,544	29
3300	Retained earnings	6(17)						
3310	Legal reserve		868,985	5	685,917	5	685,917	5
3320	Special reserve		19,760	-	27,786	-	27,786	-
3350	Unappropriated retained earnings		5,389,257	34	5,222,920	36	4,814,526	33
3400	Other equity interest		(105,647)	(1)	(19,760)	-	(13,026)	-
36xx	Non-controlling interests	6(17)	98,103	1	92,288	1	83,955	1
	Total equity		11,320,002	71	11,058,695	76	10,648,702	73
	Total liabilities and equity		\$15,942,918	100	\$14,545,763	100	\$14,507,857	100

(The accompanying notes are an integral part of the consolidated financial statements.)

Pegavision Corporation and Subsidiaries
Consolidated Statements of Comprehensive Incomes
For the three-month and nine-month periods ended September 30, 2025 and 2024
(Amounts Expressed in Thousands of New Taiwan Dollars, Except for Earnings per Share)

Code	Items	Notes	For the three-month period ended September 30,				For the nine-month period ended September 30,			
			2025		2024		2025		2024	
			Amount	%	Amount	%	Amount	%	Amount	%
4000	Operating revenue	6(18), 7	\$1,888,685	100	\$1,659,030	100	\$5,108,998	100	\$5,022,500	100
5000	Operating costs	6(6), 7	(931,989)	(49)	(762,289)	(46)	(2,446,024)	(48)	(2,178,753)	(43)
5900	Gross profit		956,696	51	896,741	54	2,662,974	52	2,843,747	57
6000	Operating expenses	7								
6100	Selling expenses		(176,216)	(9)	(159,782)	(10)	(532,685)	(10)	(496,776)	(10)
6200	Administrative expenses		(136,699)	(7)	(105,655)	(6)	(366,066)	(8)	(311,447)	(7)
6300	Research and development expenses		(161,593)	(9)	(161,424)	(10)	(472,205)	(9)	(475,942)	(9)
6450	Expected credit gains (losses)	6(19)	(1,995)	-	(288)	-	(1,845)	-	41,568	1
	Operating expenses total		(476,503)	(25)	(427,149)	(26)	(1,372,801)	(27)	(1,242,597)	(25)
6900	Operating income		480,193	26	469,592	28	1,290,173	25	1,601,150	32
7000	Non-operating income and expenses	6(7), 6(22), 7								
7100	Interest income		10,643	-	5,976	-	33,682	1	16,485	-
7010	Other income		16,670	1	11,585	1	159,445	3	28,135	1
7020	Other gains or losses		12,218	1	46,239	3	27,687	2	48,590	2
7050	Finance costs		(14,430)	(1)	(14,901)	(1)	(39,902)	(1)	(44,291)	(1)
7060	Share of profit or loss of associates and joint ventures accounted		(58)	-	(44)	-	(220)	-	(40)	-
	Total non-operating incomes and expenses		25,043	1	48,855	3	180,692	4	48,879	1
7900	Income from continuing operations before income tax		505,236	27	518,447	31	1,470,865	29	1,650,029	33
7950	Income tax	4, 6(24)	(102,722)	(6)	(74,417)	(4)	(254,418)	(5)	(209,999)	(4)
8200	Net income		402,514	21	444,030	27	1,216,447	24	1,440,030	29
8300	Other comprehensive income (loss)	6(23)								
8360	Items that may be reclassified subsequently to profit or loss									
8380	Exchange differences resulting from translating the financial statements of a foreign operation		15,092	1	9,998	-	(88,237)	(2)	15,967	-
8399	Income tax relating to components of other comprehensive income		-	-	(16)	-	97	-	(58)	-
	Total other comprehensive income, net of tax		15,092	1	9,982	-	(88,140)	(2)	15,909	-
8500	Total comprehensive income		<u>\$417,606</u>	<u>22</u>	<u>\$454,012</u>	<u>27</u>	<u>\$1,128,307</u>	<u>22</u>	<u>\$1,455,939</u>	<u>29</u>
8600	Net income (loss) attributable to:									
8610	Shareholders of the parent		\$396,729	21	\$437,770	27	\$1,199,379	24	\$1,422,282	29
8620	Non-controlling interests		5,785	-	6,260	-	17,068	-	17,748	-
			<u>\$402,514</u>	<u>21</u>	<u>\$444,030</u>	<u>27</u>	<u>\$1,216,447</u>	<u>24</u>	<u>\$1,440,030</u>	<u>29</u>
8700	Comprehensive income (loss) attributable to:									
8710	Shareholders of the parent		\$411,009	22	\$447,898	27	\$1,113,492	22	\$1,437,042	29
8720	Non-controlling interests		6,597	-	6,114	-	14,815	-	18,897	-
			<u>\$417,606</u>	<u>22</u>	<u>\$454,012</u>	<u>27</u>	<u>\$1,128,307</u>	<u>22</u>	<u>\$1,455,939</u>	<u>29</u>
9750	Earnings per share-basic (in NTD)	6(25)	<u>\$5.09</u>		<u>\$5.61</u>		<u>\$15.38</u>		<u>\$18.23</u>	
9850	Earnings per share-diluted (in NTD)	6(25)	<u>\$5.05</u>		<u>\$5.58</u>		<u>\$15.24</u>		<u>\$18.11</u>	

(The accompanying notes are an integral part of the consolidated financial statements.)

Pegavision Corporation and Subsidiaries
Consolidated Statements of Changes in Equity
For the nine-month periods ended September 30, 2025 and 2024
(Amounts Expressed In Thousands of New Taiwan Dollars)

Code	Items	Equity Attributable to Shareholders of the Parent						Total	Non-controlling Interests	Total Equity
		Capital	Capital Surplus	Retained Earnings			Other Equity interest			
				Legal Reserve	Special reserve	Unappropriated Earnings	Exchange differences arising on translation of foreign operations			
		3100	3200	3310	3320	3350	3410	31XX	36XX	3XXX
A1	Balance as of January 1, 2024	\$780,000	\$4,269,521	\$520,327	\$12,934	\$4,352,686	\$(27,786)	\$9,907,682	\$72,558	\$9,980,240
	Appropriation and distribution of 2023 earnings									
B1	Legal reserve appropriated			165,590		(165,590)		-		-
B3	Special reserve appropriated				14,852	(14,852)		-		-
B5	Cash dividends-common share					(780,000)		(780,000)		(780,000)
C7	Changes in associates and joint ventures accounted for using the equity method		23					23		23
D1	Net income (loss) for the nine-month period ended September 30, 2024					1,422,282		1,422,282	17,748	1,440,030
D3	Other comprehensive income (loss), net of tax, for the nine-month period ended September 30, 2024						14,760	14,760	1,149	15,909
D5	Total comprehensive income (loss)	-	-	-	-	1,422,282	14,760	1,437,042	18,897	1,455,939
O1	Non-controlling interests								(7,500)	(7,500)
Z1	Balance as of September 30, 2024	<u>\$780,000</u>	<u>\$4,269,544</u>	<u>\$685,917</u>	<u>\$27,786</u>	<u>\$4,814,526</u>	<u>\$(13,026)</u>	<u>\$10,564,747</u>	<u>\$83,955</u>	<u>\$10,648,702</u>
A1	Balance as of January 1, 2025	\$780,000	\$4,269,544	\$685,917	\$27,786	\$5,222,920	\$(19,760)	\$10,966,407	\$92,288	\$11,058,695
	Appropriation and distribution of 2024 earnings									
B1	Legal reserve appropriated			183,068		(183,068)		-		-
B5	Cash dividends-common share					(858,000)		(858,000)		(858,000)
B17	Reversal of special reserve				(8,026)	8,026		-		-
D1	Net income (loss) for the nine-month period ended September 30, 2025					1,199,379		1,199,379	17,068	1,216,447
D3	Other comprehensive income (loss), net of tax, for the nine-month period ended September 30, 2025						(85,887)	(85,887)	(2,253)	(88,140)
D5	Total comprehensive income (loss)	-	-	-	-	1,199,379	(85,887)	1,113,492	14,815	1,128,307
O1	Non-controlling interests								(9,000)	(9,000)
Z1	Balance as of September 30, 2025	<u>\$780,000</u>	<u>\$4,269,544</u>	<u>\$868,985</u>	<u>\$19,760</u>	<u>\$5,389,257</u>	<u>\$(105,647)</u>	<u>\$11,221,899</u>	<u>\$98,103</u>	<u>\$11,320,002</u>

(The accompanying notes are an integral part of the consolidated financial statements.)

Pegavision Corporation and Subsidiaries
Consolidated Statements of Cash Flows
For the nine-month periods ended September 30, 2025 and 2024
(Amounts Expressed in Thousands of New Taiwan Dollars)

Code	Items	For the nine-month periods ended September 30,		Code	Items	For the nine-month periods ended September 30,	
		2025	2024			2025	2024
AAAA	Cash flows from operating activities:			BBBB	Cash flows from investing activities:		
A10000	Income before income tax	\$1,470,865	\$1,650,029	B00010	Disposal (acquisition) of financial assets at fair value through other comprehensive income	(50,880)	-
A20000	Adjustments:						
A20010	Profit or loss not effecting cash flows:			B00040	Disposal (acquisition) of financial assets measured at amortized cost	(691,469)	1,093,300
A20100	Depreciation (including right-of-use assets)	539,030	542,756	B02700	Acquisition of property, plant and equipment	(1,109,035)	(3,002,775)
A20200	Amortization	17,246	13,116	B02800	Proceeds from disposal of property, plant and equipment	76	30
A20300	Expected credit losses (gain)	1,845	(41,568)	B03800	(Increase) decrease in refundable deposits	(980)	13,365
A20400	Net loss (gain) of financial assets (liabilities) at fair value through profit or loss	(11,994)	(24,372)	B04500	Acquisition of intangible assets	(28,810)	(13,314)
A20900	Interest expense	39,902	44,291	B05350	Acquisition of right-of use assets	-	(112,584)
A21200	Interest income	(33,682)	(16,485)	BBBB	Net cash provided by (used in) investing activities	(1,881,098)	(2,021,978)
A22300	Share of profit or loss of associates and joint ventures	220	40	CCCC	Cash flows from financing activities:		
A22500	Loss (gain) on disposal of property, plant and equipment	5,771	192	C00100	Increase in (repayment of) short-term borrowings	528,926	(240,076)
A23700	Impairment loss on non-financial assets	-	19,242	C01600	Increase in long-term borrowings	-	193,700
A29900	Gain on lease modification	(568)	(1,636)	C01700	Repayment of long-term borrowings	(102,188)	(53,023)
A29900	Gain on government grants	(218)	(238)	C03000	Increase (decrease) in guarantee deposits received	31	2,396
A30000	Changes in operating assets and liabilities:			C04020	Payments of lease liabilities	(29,009)	(55,869)
A31115	Financial assets at fair value through profit or loss	210,807	1,081,733	C04500	Dividend distribution	(858,000)	(780,000)
A31150	Accounts receivable	(262,433)	84,959	C05800	Non-controlling interests change	(9,000)	(7,342)
A31180	Other receivables	(14,321)	(366)	CCCC	Net cash provided by (used in) financing activities	(469,240)	(940,214)
A31200	Inventories	(119,182)	(197,706)				
A31230	Prepayments	(4,918)	(10,543)	DDDD	Effect of exchange rate changes	(40,073)	13,059
A31240	Other current assets	(37,435)	(13,359)				
A32125	Contract liabilities	13,386	19,312	EEEE	Increase (decrease) in cash and cash equivalents	(347,894)	109,661
A32130	Notes payable	(657)	3,199	E00100	Cash and cash equivalents at beginning of period	2,002,176	1,500,502
A32150	Accounts payable	93,352	(36,442)	E00200	Cash and cash equivalents at end of period	\$1,654,282	\$1,610,163
A32180	Other payables	229,815	224,642				
A32200	Provision	3,600	-				
A32230	Other current liabilities	39,932	36,453				
A33000	Cash generated from operations	2,180,363	3,377,249				
A33100	Interest received	32,016	21,379				
A33300	Interest paid	(36,865)	(44,715)				
A33500	Income tax paid	(132,997)	(295,119)				
AAAA	Net cash provided by (used in) operating activities	2,042,517	3,058,794				

(The accompanying notes are an integral part of the consolidated financial statements.)

1. HISTORY AND ORGANIZATION

Pegavision Corporation (referred to “the Company”) was established on August 12, 2009. Its main business activities include the manufacture of medical device, optical instrument, precision instrument and sales of the previous related products. The Company’s stocks have been governmentally approved on October 7, 2014 to be listed and traded in Taiwan Over-The-Counter Securities Exchanges starting December 30, 2014 and traded in Taiwan Stock Exchange starting on October 7, 2019. The registered business premise and main operation address is at No.5 Shing Yeh Street, GuiShan District, Taoyuan City, Taiwan 33341.

Kinsus Interconnect Technology Corp. is the Company’s parent, while Pegatron Corporation is the ultimate controller of the Group to which the Company belongs.

2. DATE AND PROCEDURE OF AUTHORIZATION OF FINANCIAL STATEMENTS FOR ISSUE

The consolidated financial statements of the Company and its subsidiaries (“the Group”) for the nine-month periods ended September 30, 2025 and 2024 were authorized for issue by the Board of Directors on October 27th, 2025.

3. NEWLY ISSUED OR REVISED STANDARDS AND INTERPRETATIONS

(1) Changes in accounting policies resulting from applying for the first time certain standards and amendments

The Group applied for the first time International Financial Reporting Standards, International Accounting Standards, and Interpretations issued, revised, or amended which are recognized by Financial Supervisory Commission (“FSC”) and become effective for annual periods beginning on or after January 1, 2025. The adoption of these new standards and amendments and interpretations of initial application has no material impact on the Group.

(2) Standards or interpretations issued, revised or amended, by International Accounting Standards Board (“IASB”) which have been endorsed by FSC, and not yet adopted by the Group as at the date when the Group’s financial statements were authorized for issue, are listed below.

Items	New, Revised or Amended Standards and Interpretations	Effective Date issued by IASB
a	IFRS 17 “Insurance Contracts”	1 January 2023
b	Amendments to the Classification and Measurement of Financial Instruments – Amendments to IFRS 9 and IFRS 7	1 January 2026
c	Annual Improvements to IFRS Accounting Standards – Volume 11	1 January 2026
d	Contracts Referencing Nature-dependent Electricity – Amendments to IFRS 9 and IFRS 7	1 January 2026

(A) IFRS 17 “Insurance Contracts”

IFRS 17 provides a comprehensive model for insurance contracts, covering all relevant accounting aspects (including recognition, measurement, presentation and disclosure requirements). The core of IFRS 17 is the General (building block) Model, under this model, on initial recognition, an entity shall measure a group of insurance contracts at the total of the fulfilment cash flows and the contractual service margin. The carrying amount of a group of insurance contracts at the end of each reporting period shall be the sum of the liability for remaining coverage and the liability for incurred claims.

Other than the General Model, the standard also provides a specific adaptation for contracts with direct participation features (the Variable Fee Approach) and a simplified approach (Premium Allocation Approach) mainly for short-duration contracts.

IFRS 17 was issued in May 2017 and it was amended in 2020 and 2021. The amendments include deferral of the date of initial application of IFRS 17 by two years to annual beginning on or after 1 January 2023 (from the original effective date of 1 January 2021); provide additional transition reliefs; simplify some requirements to reduce the costs of applying IFRS 17 and revise some requirements to make the results easier to explain. IFRS 17 replaces an interim Standard – IFRS 4 Insurance Contracts – from annual reporting periods beginning on or after 1 January 2023.

(B) Amendments to the Classification and Measurement of Financial Instruments –
Amendments to IFRS 9 and IFRS 7

The amendments include:

- (a) Clarify that a financial liability is derecognised on the settlement date and describe the accounting treatment for settlement of financial liabilities using an electronic payment system before the settlement date.
- (b) Clarify how to assess the contractual cash flow characteristics of financial assets that include environmental, social and governance (ESG)-linked features and other similar contingent features.
- (c) Clarify the treatment of non-recourse assets and contractually linked instruments.
- (d) Require additional disclosures in IFRS 7 for financial assets and liabilities with contractual terms that reference a contingent event (including those that are ESG-linked), and equity instruments classified at fair value through other comprehensive income.

(C) Annual Improvements to IFRS Accounting Standards – Volume 11

- (a) Amendments to IFRS 1
- (b) Amendments to IFRS 7
- (c) Amendments to Guidance on implementing IFRS 7
- (d) Amendments to IFRS 9
- (e) Amendments to IFRS 10
- (f) Amendments to IAS 7

(D) Contracts Referencing Nature-dependent Electricity – Amendments to IFRS 9 and IFRS 7

The amendments include:

- (a) Clarify the application of the ‘own-use’ requirements.
- (b) Permit hedge accounting if these contracts are used as hedging instruments.
- (c) Add new disclosure requirements to enable investors to understand the effect of these contracts on a company’s financial performance and cash flows.

The abovementioned standards and amendments are applicable for annual periods beginning on or after January 1, 2026 and have no material impact on the Group.

(3) Standards or interpretations issued, revised or amended, by IASB which have not been endorsed by FSC, and not yet adopted by the Group as at the date when the Group’s financial statements were authorized for issue, are listed below.

Items	New, Revised or Amended Standards and Interpretations	Effective Date issued by IASB
a	IFRS 10 “Consolidated Financial Statements” and IAS 28 “Investments in Associates and Joint Ventures” — Sale or Contribution of Assets between an Investor and its Associate or Joint Ventures	To be determined by IASB
b	IFRS 18 “Presentation and Disclosure in Financial Statements”	January 1, 2027 (Note)
c	Disclosure Initiative – Subsidiaries without Public Accountability: Disclosures (IFRS 19)	January 1, 2027

Note: On 25 September 2025, the FSC announced in a press release that Taiwan will adopt IFRS 18 in 2028.

(A) IFRS 10 “Consolidated Financial Statements” and IAS 28 “Investments in Associates and Joint Ventures” — Sale or Contribution of Assets between an Investor and its Associate or Joint Ventures

The amendments address the inconsistency between the requirements in IFRS 10 Consolidated Financial Statements and IAS 28 Investments in Associates and Joint Ventures, in dealing with the loss of control of a subsidiary that is contributed to an associate or a joint venture. IAS 28 restricts gains and losses arising from contributions of non-monetary assets to an associate or a joint venture to the extent of the interest attributable to the other equity holders in the associate or joint ventures. IFRS 10 requires full profit or loss recognition on the loss of control of the subsidiary. IAS 28 was amended so that the gain or loss resulting from the sale or contribution of assets that constitute a business as defined in IFRS 3 between an investor and its associate or joint venture is recognized in full.

IFRS 10 was also amended so that the gains or loss resulting from the sale or contribution of a subsidiary that does not constitute a business as defined in IFRS 3 between an investor and its associate or joint venture is recognized only to the extent of the unrelated investors’ interests in the associate or joint venture.

(B) IFRS 18 “Presentation and Disclosure in Financial Statements”

IFRS 18 replaces IAS 1 Presentation of Financial Statements. The main changes are as below:

(a) Improved comparability in the statement of profit or loss (income statement)

IFRS 18 requires entities to classify all income and expenses within their statement of profit or loss into one of five categories: operating; investing; financing; income taxes; and discontinued operations. The first three categories are new, to improve the structure of the income statement, and requires all entities to provide new defined subtotals, including operating profit or loss. The improved structure and new subtotals will give investors a consistent starting point for analyzing entities’ performance and make it easier to compare entities.

(b) Enhanced transparency of management-defined performance measures

IFRS 18 requires entities to disclose explanations of those entity-specific measures that are related to the income statement, referred to as management-defined performance measures.

(c) Useful grouping of information in the financial statements

IFRS 18 sets out enhanced guidance on how to organize information and whether to provide it in the primary financial statements or in the notes. The changes are expected to provide more detailed and useful information. IFRS 18 also requires entities to provide more transparency about operating expenses, helping investors to find and understand the information they need.

(C) Disclosure Initiative – Subsidiaries without Public Accountability: Disclosures (IFRS 19)

This new standard and its amendments permit subsidiaries without public accountability to provide reduced disclosures when applying IFRS Accounting Standards in their financial statements. IFRS 19 is optional for subsidiaries that are eligible and sets out the disclosure requirements for subsidiaries that elect to apply it.

The abovementioned standards and interpretations issued by IASB have not yet endorsed by FSC at the date when the Group's financial statements were authorized for issue, the local effective dates are to be determined by FSC. As the Group is still currently determining the potential impact of the new or amended standards and interpretations listed under (B), it is not practicable to estimate their impact on the Group at this point in time. The remaining new or amended standards and interpretations have no material impact on the Group.

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(1) Statement of compliance

The consolidated financial statements of the Group for the nine-month periods ended September 30, 2025 and 2024 have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers ("the Regulations") and IAS 34 Interim Financial Reporting as endorsed and became effective by the FSC.

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Except the following 4(3) ~ 4(5), the accounting policies applied in these consolidated financial statements are consistent with those applied in the consolidated financial statements for the year ended December 31, 2024. For more details, please refer to Note 4 of the Company's consolidated financial statements for the year ended December 31, 2024.

(2)Basis of preparation

The consolidated financial statements have been prepared on a historical cost basis, except for financial instruments that have been measured at fair value. The consolidated financial statements are presented in thousands of New Taiwan Dollars ("NT\$") unless otherwise specified.

(3)Basis of consolidation

The same principles of consolidation have been applied in the Company's consolidated financial statements as those applied in the Company's consolidated financial statements for the year ended December 31, 2024. For the principles of consolidation, please refer to Note 4(3) of the Company's consolidated financial statements for the year ended December 31, 2024.

The consolidated entities are listed as follows:

Investor	Subsidiary	Main business	Percentage of Ownership (%)			Note
			30 Sep. 2025	31 Dec. 2024	30 Sep. 2024	
The Company	Pegavision Japan Inc.	Selling medical equipment	100.00%	100.00%	100.00%	None
The Company	Pegavision (Jiangsu) Limited	Producing and selling medical equipment	100.00%	100.00%	100.00%	None
The Company	Mayin Investment Co., Ltd.	Investing activities	100.00%	100.00%	100.00%	None

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Investor	Subsidiary	Main business	Percentage of Ownership (%)			Note
			30 Sep. 2025	31 Dec. 2024	30 Sep. 2024	
The Company	PEGAVISION VIETNAM COMPANY LIMITED	Producing and selling medical equipment	100.00%	100.00%	100.00%	None
The Company	Pegavision (Shanghai) Limited	Selling medical equipment	100.00%	100.00%	100.00%	Note1
The Company	PEGAVISION NETHERLANDS B.V.	Selling medical equipment	100.00%	-	-	Note 2
Mayin Investment Co., Ltd.	BeautyTech Platform Corporation	Selling medical equipment and cosmetic products	85.00%	85.00%	85.00%	None
Mayin Investment Co., Ltd.	FacialBeau International Corporation	Selling medical equipment and cosmetic products	55.00%	55.00%	55.00%	None
BeautyTech Platform Corporation	Pegavision (Shanghai) Limited	Selling medical equipment	-	100.00%	100.00%	Note 3
BeautyTech Platform Corporation	BeautyTech Platform (Shanghai) Corporation	Selling medical equipment and cosmetic products	100.00%	100.00%	100.00%	Note 3

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Investor	Subsidiary	Main business	Percentage of Ownership (%)			Note
			30 Sep. 2025	31 Dec. 2024	30 Sep. 2024	
BeautyTech Platform Corporation	BEAUTYTECH PLATFORM (SINGAPORE) PTE. LTD.	Selling medical equipment and cosmetic products	-	100.00%	100.00%	Note 4
BeautyTech Platform Corporation	FORIMART Corporation	Selling medical equipment and cosmetic products	100.00%	100.00%	100.00%	None
BeautyTech Platform Corporation	BEAUTYTECH PLATFORM (VIETNAM) LIMITED LIABILITY COMPANY	Selling medical equipment and cosmetic products	70.00%	70.00%	-	Note 1
Pegavision (Shanghai) Limited	Gemvision Technology (Zhejiang) Limited	Selling medical equipment	-	100.00%	100.00%	Note 3
BeautyTech Platform (Shanghai) Corporation	Gemvision Technology (Zhejiang) Limited	Selling medical equipment	100.00%	-	-	Note 3
FacialBeau International Corporation	FacialBeau (Jiangsu) Corporation	Selling medical equipment and cosmetic products	100.00%	100.00%	100.00%	Note 1

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Investor	Subsidiary	Main business	Percentage of Ownership (%)			Note
			30 Sep. 2025	31 Dec. 2024	30 Sep. 2024	
FacialBeau International Corporation	IKIDO Inc.	Selling medical equipment and cosmetic products	100.00%	100.00%	100.00%	None
FacialBeau International Corporation	RODNA Co., Ltd.	Selling medical equipment and cosmetic products	100.00%	100.00%	100.00%	None
FacialBeau International Corporation	Aquamax Vision Corporation	Selling medical equipment and cosmetic products	100.00%	100.00%	100.00%	None

Note 1: To improve the synergy of the Group, the board of directors decided to reorganize and set up the Subsidiaries on July 26, 2021:

(a)FacialBeau (Jiangsu) Corporation which is 100% held by FacialBeau International Corporation was registered on February 25, 2022. The investment amount has not been remitted as of September 30, 2025.

(b)Pegavision (Shanghai) Company Limited which is 100% held by the Company was registered on April 23, 2024. The investment amount has not been remitted as of September 30, 2025.

(c)BEAUTYTECH PLATFORM (VIETNAM) LIMITED LIABILITY COMPANY which is 70% held by BeautyTech Platform Corporation was registered on October 9, 2024.

Note 2: To develop the European market, the board of directors resolved on December 31, 2024 to set up PEGAVISION NETHERLANDS B.V., which was 100% directly held by the company. The registration was completed on February 28, 2025.

Note 3: As part of the Group's business reorganization, BeautyTech Platform (Shanghai) Corporation has merged with Pegavision (Shanghai) Limited in 2025. BeautyTech Platform (Shanghai) Corporation is the surviving entity, and Pegavision (Shanghai) Limited was dissolved upon the completion of the merger.

Note 4: BEAUTYTECH PLATFORM (SINGAPORE) PTE. LTD. has completed the cancellation of registration in 2025 due to group business adjustments.

(4)Provisions

Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Group expects some or all of a provision to be reimbursed, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

The liability to pay a levy is recognized progressively if the obligating event occurs over a period of time.

(5)Income taxes

Interim period income tax expense is accrued using the tax rate that would be applicable to expected total annual earnings, that is, the estimated average annual effective income tax rate applied to the pre-tax income of the interim period. The estimated average annual effective income tax rate only includes current income tax. The recognition and measurement of deferred tax follows annual financial reporting requirements in accordance with IAS 12. The Group recognizes the effect of change in tax rate for deferred taxes in full if the new tax rate is enacted by the end of the interim reporting period, by charging to profit or loss, other comprehensive income, or directly to equity.

5. SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS

The preparation of the consolidated financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities at the end of the reporting period. However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

The same significant accounting judgments, estimates and assumptions have been applied in the Company's consolidated financial statements for the nine-month period ended September 30, 2025, as those applied in the Company's consolidated financial statements for the year ended December 31, 2024. For significant accounting judgments, estimates and assumptions, please refer to Note 5 of the Company's consolidated financial statements for the year ended December 31, 2024.

6. CONTENTS OF SIGNIFICANT ACCOUNTS

(1) Cash and cash equivalents

	As of		
	30 Sep. 2025	31 Dec. 2024	30 Sep. 2024
Cash and petty cash	\$5,657	\$4,881	\$5,013
Checkings and savings	604,863	533,273	451,951
Time deposit(note)	1,043,762	1,464,022	1,153,199
Total	<u>\$1,654,282</u>	<u>\$2,002,176</u>	<u>\$1,610,163</u>

Note: The contract will expire within three months and it must be readily convertible to a known amount of cash and be subject to an insignificant risk of changes in value.

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(2) Financial assets at fair value through profit or loss

	As of		
	30 Sep. 2025	31 Dec. 2024	30 Sep. 2024
Mandatorily measured at fair value through profit or loss:			
Money market fund	\$915,544	\$1,116,752	\$1,571,596
Valuation adjustment	7,021	4,626	6,508
Total	<u>\$922,565</u>	<u>\$1,121,378</u>	<u>\$1,578,104</u>
Current	\$922,565	\$1,121,378	\$1,578,104
Non-current	-	-	-
Total	<u>\$922,565</u>	<u>\$1,121,378</u>	<u>\$1,578,104</u>

No financial asset measured at fair value through profit or loss was pledged as collateral.

(3) Financial assets at fair value through other comprehensive income

	As of		
	30 Sep. 2025	31 Dec. 2024	30 Sep. 2024
Equity instrument investments measured at fair value through other comprehensive income – Non-current:			
Unlisted companies stocks	<u>\$50,880</u>	<u>\$-</u>	<u>\$-</u>

No financial assets at fair value through other comprehensive income were pledged as collateral.

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(4) Financial asset measured at amortized cost

	As of		
	30 Sep. 2025	31 Dec. 2024	30 Sep. 2024
Time deposit	\$1,826,401	\$1,134,932	\$1,005,069
Less: loss allowance	-	-	-
Total	<u>\$1,826,401</u>	<u>\$1,134,932</u>	<u>\$1,005,069</u>
Current	<u>\$1,825,242</u>	<u>\$1,134,932</u>	<u>\$1,005,069</u>
Non-current	<u>\$1,159</u>	<u>\$-</u>	<u>\$-</u>

The Group deals with financial institution with good credit condition, there is no significant credit risk.

No financial asset measured at amortized cost was pledged as collateral.

(5) Accounts receivable, net

A. Accounts receivable, net

	As of		
	30 Sep. 2025	31 Dec. 2024	30 Sep. 2024
Accounts receivable, gross	\$1,075,237	\$812,804	\$794,426
Less: loss allowance	(8,445)	(6,616)	(6,778)
Total accounts receivable, net	<u>\$1,066,792</u>	<u>\$806,188</u>	<u>\$787,648</u>

B. Receivable were not pledged.

C. Accounts receivables are generally on T/T to 90 days terms. The total carrying amount is NT\$1,075,237 thousand, NT\$812,804 thousand and NT\$794,426 thousand as of September 30, 2025, December 31, 2024, and September 30, 2024, respectively. Please refer to Note 6 (19) for more details on loss allowance of accounts receivable for the nine-month periods ended September 30, 2025, and 2024. Please refer to Note 12 for more details on credit risk management.

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(6) Inventory

A. Details of inventory:

	As of		
	30 Sep. 2025	31 Dec. 2024	30 Sep. 2024
Merchandises	\$52,822	\$35,774	\$34,404
Raw materials	114,880	88,253	94,622
Supplies	10,916	5,071	7,372
Work in process	273,946	200,993	239,892
Finished goods	337,641	340,932	404,895
Total	<u>\$790,205</u>	<u>\$671,023</u>	<u>\$781,185</u>

B. For the three-month periods ended September 30, 2025 and 2024, the Group recognized NT\$931,989 thousand and NT\$762,289 thousand under the caption of costs of sale, respectively. For the nine-month periods ended September 30, 2025 and 2024, the Group recognized NT\$2,446,024 thousand and NT\$2,178,753 thousand under the caption of costs of sale, respectively. The following items were also included in cost:

Item	For the three-month period ended Sep 30,		For the nine-month period ended Sep 30,	
	2025	2024	2025	2024
Loss (gain) from inventory market decline	\$(4,467)	\$(7,550)	\$24,086	\$(4,464)
Loss from inventory write-off obsolescence	9,890	13,007	12,306	14,499
Total	<u>\$5,423</u>	<u>\$5,457</u>	<u>\$36,392</u>	<u>\$10,035</u>

The Group recognized gains on recovery of inventory market decline because some of the inventories previously provided with market loss or obsolescence were disposed.

C. The inventories were not pledged.

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(7) Investments accounted for under the equity method

The following table lists the investments accounted for using the equity method of the Group:

Investees	As of						Note
	Sep. 30, 2025		Dec. 31, 2024		Sep. 30, 2024		
	Percentage		Percentage		Percentage		
	Carrying amount	of ownership	Carrying amount	of ownership	Carrying amount	of ownership	
<u>Unlisted company</u>							
Zhuhe Investment Co., Ltd.	\$19,531	10%	\$19,751	10%	\$19,800	10%	None

A. Investments in associates

The information regarding non-significant associates of the Group is as follows:

In August 2023, the Group invested cash in Zhuhe Investment Co., Ltd., holding 11.76% ownership and was appointed one seat of directorship. Therefore, the Group only has material influence but does not have control over Zhuhe Investment Co., Ltd.

Zhuhe Investment Co., Ltd. conducted a cash capital increase in June 2024. The Group did not subscribe to the shares proportionately, thereby reducing its ownership from 11.76% to 10%. An additional capital surplus in the amount of NT\$23 thousand was recognized for the non-proportionate subscription.

As of September 30, 2025 and December 31, 2024 and September 30, 2024, the aggregated carrying amount of the Group's investment in Zhuhe Investment Co., Ltd. amounted to NT\$19,531 thousand, NT\$19,751 thousand and NT\$19,800 thousand. The summarized financial information for the share of associates of the Group is as follows:

	For the three-month period		For the nine-month period	
	September 30		September 30	
	2025	2024	2025	2024
Profit (loss) from continuing operations	\$(58)	\$(44)	\$(220)	\$(40)
Other comprehensive income (post-tax)	-	-	-	-
Total comprehensive loss	<u>\$(58)</u>	<u>\$(44)</u>	<u>\$(220)</u>	<u>\$(40)</u>

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

- B. The associates and jointly controlled entities had no contingent liabilities or capital commitments and they were not pledged.

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(8)Property, plant, and equipment

	Land	Buildings	Machinery and equipment	Transportation equipment	Computer equipment	Office equipment	Other equipment	Construction in progress and equipment awaiting inspection (including prepayment for equipment)	Total
<u>Cost:</u>									
As of 1/1/2025	\$3,435,281	\$1,375,667	\$4,965,274	\$1,973	\$94,639	\$2,459	\$1,510,266	\$1,775,809	\$13,161,368
Addition	-	5,778	-	-	-	-	1,704	1,316,413	1,323,895
Disposals	-	-	(102,643)	-	(3,939)	-	(29,789)	-	(136,371)
Transfer	-	1,678,305	197,132	218	37,018	(114)	848,721	(2,761,280)	-
Effect of EX rate	(180)	(3,888)	-	-	(143)	(62)	(6,089)	(12,897)	(23,259)
As of 9/30/2025	<u>\$3,435,101</u>	<u>\$3,055,862</u>	<u>\$5,059,763</u>	<u>\$2,191</u>	<u>\$127,575</u>	<u>\$2,283</u>	<u>\$2,324,813</u>	<u>\$318,045</u>	<u>\$14,325,633</u>
As of 1/1/2024	\$1,522,877	\$170,165	\$4,921,250	\$1,973	\$86,656	\$2,532	\$1,078,370	\$2,065,196	\$9,849,019
Addition	-	-	-	-	-	-	1,505	3,040,370	3,041,875
Disposals	-	-	(4,850)	-	(459)	-	(6,214)	-	(11,523)
Transfer	1,912,674	1,142,404	32,128	-	5,994	-	347,336	(3,440,536)	-
Effect of EX rate	197	108	-	-	96	62	3,386	155	4,004
As of 9/30/2024	<u>\$3,435,748</u>	<u>\$1,312,677</u>	<u>\$4,948,528</u>	<u>\$1,973</u>	<u>\$92,287</u>	<u>\$2,594</u>	<u>\$1,424,383</u>	<u>\$1,665,185</u>	<u>\$12,883,375</u>

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

	Land	Buildings	Machinery and equipment	Transportation equipment	Computer equipment	Office equipment	Other equipment	Construction in progress and equipment awaiting inspection (including prepayment for equipment)	Total
<u>Depreciation and impairment:</u>									
As of 1/1/2025	\$-	\$106,921	\$3,980,252	\$1,567	\$85,887	\$229	\$903,286	\$-	\$5,078,142
Depreciation	-	53,047	310,012	161	5,312	110	137,540	-	506,182
Impairment loss	-	-	-	-	-	-	-	-	-
Disposal	-	-	(98,303)	-	(3,939)	-	(28,282)	-	(130,524)
Transfer	-	-	-	-	-	-	-	-	-
Effect of EX rate	-	(86)	-	-	(132)	(10)	(1,721)	-	(1,949)
As of 9/30/2025	<u>\$-</u>	<u>\$159,882</u>	<u>\$4,191,961</u>	<u>\$1,728</u>	<u>\$87,128</u>	<u>\$329</u>	<u>\$1,010,823</u>	<u>\$-</u>	<u>\$5,451,851</u>
As of 1/1/2024	\$-	\$52,979	\$3,522,598	\$1,366	\$80,732	\$32	\$776,230	\$-	\$4,433,937
Depreciation	-	23,009	362,325	152	3,994	147	96,294	-	485,921
Impairment loss	-	19,242	-	-	-	-	-	-	19,242
Disposal	-	-	(4,850)	-	(459)	-	(5,992)	-	(11,301)
Transfer	-	-	-	-	-	-	-	-	-
Effect of EX rate	-	9	-	-	56	7	640	-	712
As of 9/30/2024	<u>\$-</u>	<u>\$95,239</u>	<u>\$3,880,073</u>	<u>\$1,518</u>	<u>\$84,323</u>	<u>\$186</u>	<u>\$867,172</u>	<u>\$-</u>	<u>\$4,928,511</u>

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

	Land	Buildings	Machinery and equipment	Transportation equipment	Computer equipment	Office equipment	Other equipment	Construction in progress and equipment awaiting inspection (including prepayment for equipment)	Total
<u>Net carrying amount:</u>									
As of 9/30/2025	\$3,435,101	\$2,895,980	\$867,802	\$463	\$40,447	\$1,954	\$1,313,990	\$318,045	\$8,873,782
As of 12/31/2024	\$3,435,281	\$1,268,746	\$985,022	\$406	\$8,752	\$2,230	\$606,980	\$1,775,809	\$8,083,226
As of 9/30/2024	\$3,435,748	\$1,217,438	\$1,068,455	\$455	\$7,964	\$2,408	\$557,211	\$1,665,185	\$7,954,864

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

A.Details of property, plant & equipment and prepayment for equipment is as follows:

	As of		
	30 Sep. 2025	31 Dec. 2024	30 Sep. 2024
Property, plant, and equipment	\$8,562,932	\$7,860,209	\$7,829,377
Prepayment for equipment	310,850	223,017	125,487
Total	<u>\$8,873,782</u>	<u>\$8,083,226</u>	<u>\$7,954,864</u>

B.No impairment loss was recognized for the three-month periods ended September 30, 2025 and 2024. For the nine-month periods ended September 30, 2025 and 2024, NT\$0 and NT\$19,242 thousand impairment loss represented the write down of certain property, plant and equipment to the recoverable amount. This has been recognized in the statement of comprehensive income. The recoverable value is measured at usage values by the individual units.

C.Please refer to Note 8 for more details on property, plant and equipment under pledged.

(9)Intangible assets

	Computer software
<u>Cost:</u>	
As of January 1, 2025	\$79,924
Additions – acquired separately	28,810
Derecognized upon retirement	(783)
Effect of EX rate	-
As of September 30, 2025	<u>\$107,951</u>
As of January 1, 2024	\$59,276
Additions – acquired separately	13,314
Derecognized upon retirement	-
Effect of EX rate	-
As of September 30, 2024	<u>\$72,590</u>

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

	<u>Computer software</u>
<u>Amortization and Impairment:</u>	
As of January 1, 2025	\$57,870
Amortization	17,246
Impairment loss	-
Derecognized upon retirement	(783)
Effect of EX rate	-
As of September 30, 2025	<u>\$74,333</u>
As of January 1, 2024	\$39,736
Amortization	13,116
Impairment loss	-
Derecognized upon retirement	-
Effect of EX rate	-
As of September 30, 2024	<u>\$52,852</u>
<u>Carrying amount, net:</u>	
As of September 30, 2025	<u>\$33,618</u>
As of December 31, 2024	<u>\$22,054</u>
As of September 30, 2024	<u>\$19,738</u>

Amounts of amortization recognized for intangible assets are as follows:

	<u>For the three-month period ended September 30,</u>		<u>For the nine-month period ended September 30,</u>	
	2025	2024	2025	2024
Manufacturing expense	\$8	\$(32)	\$29	\$94
Administrative expense	5,516	4,561	15,770	12,293
Research and development expense	490	440	1,447	729
Total	<u>\$6,014</u>	<u>\$4,969</u>	<u>\$17,246</u>	<u>\$13,116</u>

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(10)Other non-current assets

	As of		
	30 Sep. 2025	31 Dec. 2024	30 Sep. 2024
Refundable deposits	\$49,989	\$49,009	\$49,566
Prepayment for equipment	310,850	223,017	125,487
Total	<u>\$360,839</u>	<u>\$272,026</u>	<u>\$175,053</u>

Please refer to Note 8 for more details on Refundable deposits under pledged.

(11)Short-term borrowings

A.Details of Short-term borrowings

	As of		
	30 Sep. 2025	31 Dec. 2024	30 Sep. 2024
Unsecured bank loans	<u>\$880,429</u>	<u>\$351,503</u>	<u>\$668,544</u>
Interest Rate (%)	4.50%~4.84%	2.02%~5.33%	1.70%~5.83%

B.The Group's unused short-term lines of credits amounts to NT\$549,295 thousand, NT\$1,106,397 thousand and NT\$778,056 thousand, As of September 30, 2025, December 31, 2024 and September 30, 2024, respectively.

(12)Other payable

	As of		
	30 Sep. 2025	31 Dec. 2024	30 Sep. 2024
Accrued expenses	\$1,794,785	\$1,564,970	\$1,678,588
Accrued interest payable	4,797	3,021	3,651
Payable to equipment suppliers	331,130	116,270	150,333
Dividends payable	-	-	158
Total	<u>\$2,130,712</u>	<u>\$1,684,261</u>	<u>\$1,832,730</u>

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(13)Provisions

	<u>Levies</u>
<u>Cost:</u>	
As of January 1, 2025	\$-
Arising during the period	3,600
Utilized	-
Unused provision reversed	-
As of September 30, 2025	<u><u>\$3,600</u></u>

A provision is recognized for the carbon fees levied in accordance with the "Climate Change Response Act" and its related sub-laws. Based on the relevant regulations and the greenhouse gases emissions within the scope in the current year's inventory, the Group is subject to the carbon fees levy. However, due to uncertainties related to factors such as emission verification or the implementation of related self-determined reduction plan , the Group has made its best estimate based on applicable regulations and available information. The payment will be made by the end of May in the following year.

(14) Other current liabilities

A.Details of other current liabilities

	<u>As of</u>		
	<u>30 Sep. 2025</u>	<u>31 Dec. 2024</u>	<u>30 Sep. 2024</u>
Other current liabilities	\$49,875	\$47,519	\$53,480
Refund liability	330,823	293,247	243,965
Deferred government grants income	12	231	297
Long-term borrowings-current portion	8,712	9,665	7,328
Total	<u><u>\$389,422</u></u>	<u><u>\$350,662</u></u>	<u><u>\$305,070</u></u>

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

B.The changes in the Group's balances of deferred government grants income are as follows:

	For the nine-month period ended September 30,	
	2025	2024
Beginning balance	\$278	\$594
Received during the period	-	-
Released to the statement of comprehensive income	(218)	(238)
Ending Balance	\$60	\$356
Current	\$12	\$297
Non-current	\$48	\$59

C.Please refer to Note 6(15) for more details on interest rate of deferred government grants income.

(15)Long-term borrowings

A.Details of long-term borrowings

Debtor	Type of Loan	Maturity	As of			Repayment
			30 Sep. 2025	31 Dec. 2024	30 Sep. 2024	
Chang Hwa Commercial Bank – Beitou Branch	Credit loan	2020.03.25-2025.03.15	\$-	\$623	\$1,247	Note 1
The Shanghai Commercial & Savings Bank – ZhongLi Branch	Secured loan	2020.11.10-2030.10.15	6,348	7,260	7,563	Note 2
The Shanghai Commercial & Savings Bank – ZhongLi Branch	Secured loan	2021.04.08-2030.10.15	25,085	28,733	29,946	Note 2
Chang Hwa Commercial Bank – Beitou Branch	Secured loan	2022.06.22-2031.06.21	96,852	167,000	167,000	Note 3

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Debtor	Type of Loan	Maturity	As of			Repayment
			30 Sep. 2025	31 Dec. 2024	30 Sep. 2024	
Mega International Commercial Bank – Lan-Ya Branch	Credit loan	2023.12.15- 2030.12.15	121,884	131,160	126,618	Note 4
Mega International Commercial Bank – Lan-Ya Branch	Credit loan	2024.03.12- 2031.03.12	91,413	98,370	94,980	Note 4
Mega International Commercial Bank – Lan-Ya Branch	Credit loan	2024.09.16- 2031.09.16	91,413	98,370	94,980	Note 4
Industrial and Commercial Bank of China	Secured loan	2024.10.09- 2034.10.08	23,372	26,913	-	Note 5
Total			456,367	558,429	522,334	
Less: current portion			(8,712)	(9,665)	(7,328)	
Non-current portion			<u>\$447,655</u>	<u>\$548,764</u>	<u>\$515,006</u>	

Note 1: A term is defined as every 1 months starting from the initial draw-down date. Grace period is 3 years (36 terms). The rest is repayable in installments of equal amount for 24 terms.

Note 2: A term is defined as every 1 months starting from the initial draw-down date. Grace period is 2 years (24 terms). The rest is repayable in installments of equal amount for 96 terms.

Note 3: A term is defined as every 1 month starting from the initial draw-down date. Grace period is 3 years (36 terms). The rest is repayable in installments of equal amount for 204 terms.

Note 4: A term is defined as every 3 months starting from the initial draw-down date. Grace period is 3 years (12 terms). The rest is repayable in installments of equal amount for 16 terms.

Note 5: A term is defined as every 1 month starting from the initial draw-down date. The rest is repayable in installments of equal amount for 120 terms.

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

B. The interest rate intervals for long-term borrowings are as follows:

	As of		
	30 Sep. 2025	31 Dec. 2024	30 Sep. 2024
The interest rate intervals (%)	1.35%~5.18%	1.15%~5.90%	1.15%~5.90%

The Group obtained from the Ministry of Economy a low-interest government loan amounting NT\$60,000 thousand with a term of 5~10 years and annual interest rates of 0.50% and monthly interest payment on the 15th of each month. The loan was recorded under the caption of other liabilities-deferred government grants income. The Group shall recognize the government grant income when it is reasonably assured that the Group satisfy all the terms of the government grant agreement.

C. Please refer to Note 8 for more details regarding assets pledged for secured bank borrowings.

(16) Post-employment benefits

Defined contribution plan

Expenses under the defined contribution plan for the three-month periods ended September 30, 2025 and 2024 were NT\$15,099 thousand and NT\$13,953 thousand, respectively. Expenses under the defined contribution plan for the nine-month periods ended September 30, 2025 and 2024 were NT\$44,059 thousand and NT\$41,679 thousand, respectively.

Defined benefits plan

Pension for the three-month periods ended September 30, 2025 and 2024 were NT\$29 thousand and NT\$13 thousand, respectively. Pension for the nine-month periods ended September 30, 2025 and 2024 were NT\$78 thousand and NT\$36 thousand, respectively.

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(17)Equity

A.Common stock

As of September 30, 2025, December 31, 2024 and September 30, 2024, the Company's authorized capital was NT\$1,000,000 thousand, and paid-in capital was NT\$780,000 thousand, each share at par value of NT\$10, divided into NT\$78,000 thousand shares. Each share has one voting right and a right to receive dividends.

B.Capital surplus

	As of		
	30 Sep. 2025	31 Dec. 2024	30 Sep. 2024
Additional paid-in capital	\$4,204,928	\$4,204,928	\$4,204,928
Changes in ownership interests in subsidiaries	4,609	4,609	4,609
Changes in associates and joint ventures accounted for using the equity method	23	23	23
Share-based payment transaction	59,359	59,359	59,359
Expired employee stock warrants	625	625	625
Total	<u>\$4,269,544</u>	<u>\$4,269,544</u>	<u>\$4,269,544</u>

According to Taiwan Company Act, the capital surplus shall not be used except for making good the deficit of the Company. When a company incurs no loss, it may distribute the capital surplus related to the income derived from the issuance of new shares at a premium or income from endowments received by the company. The distribution could be made in cash or in the form of dividend shares to its shareholders in proportion to the number of shares being held by each of them. Capital surplus related to long-term equity investments cannot be used for any purpose.

C.Appropriation of earnings and dividend policies

a.Distribution of earnings

According to the Company's Articles of Incorporation, current year's earnings, if any, shall be distributed in the following order:

- I. Payment of all taxes and dues;
- II.Offset prior years' operation losses;
- III.Set aside 10% of the remaining amount as legal reserve. There is no requirement to further make such reserve when legal reserve reaches the capital amount.
- IV.Set aside or reverse special reserve in accordance with law and regulations; and
- V.The distribution of the remaining portion, if any, will be recommended by the Board of Directors and resolved in the shareholders' meeting.

If the above-mentioned dividends are distributed to shareholders in the form of cash, the Board of Directors have been authorized to approve by a resolution adopted by a majority vote at a meeting of Board of Directors attended by two-thirds of the total number of directors, and report to the shareholder's meeting.

b.Dividend policies

The Company is in an industry with versatile environment. For long-term finance planning requirements and to meet the shareholders' demand for cash, the Group's dividend policy aims for steadiness and balancing. Dividends to be distributed in cash for each year shall not be less than 10% of the total dividends paid.

c.Legal reserve

According to the Company Act, legal reserve shall be set aside until such amount equal total authorized capital. Legal reserve can be used to offset deficits. If the Company does not incur any loss, the portion of legal reserve exceeding 25% of the paid-in capital may be distributed to shareholders by issuing new shares or by cash in proportion to the number of shares held by each shareholder.

d. Special reserve

When the Company distributing distributable earnings, it shall set aside to special reserve, an amount equal to “other net deductions from shareholders” equity for the current fiscal year, provided that if the Company has already set aside special reserve according to the requirements for the adoption of IFRS, it shall set aside supplemental special reserve based on the difference between the amount already set aside and other net deductions from shareholders’ equity. For any subsequent reversal of other net deductions from shareholders’ equity, the amount reversed may be distributed from the special reserve.

The FSC issued Order No. Financial-Supervisory-Securities-Corporate-1090150022 on March 31, 2021, which sets out the following provisions for compliance:

On a public company's first-time adoption of the IFRS, for any unrealized revaluation gains and cumulative translation adjustments (gains) recorded to shareholders’ equity that the company elects to transfer to retained earnings by application of the exemption under IFRS 1, the company shall set aside special reserve. For any subsequent use, disposal or reclassification of related assets, the company can reverse the special reserve by proportion and transfer to retained earnings.

The Company did not incur any special reserve upon the first-time adoption of T-IFRS.

- e. The appropriations of earnings for the Years 2024 and 2023 were approved through the shareholders’ meetings held on May 21, 2025 and May 24, 2024, respectively. The details of the distributions are as follows.

	Appropriation of earnings		Dividend per share (in NT\$)	
	2024	2023	2024	2023
Legal reserve	\$183,068	\$165,590		
Special reserve (reversal)	(8,026)	14,852		
Cash dividend	858,000	780,000	\$11.0	\$10.0

Please refer to Note 6(21) for details on employees’ compensation and remuneration to directors and supervisors.

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

D.Non-controlling interests

	For the nine-month period ended September 30,	
	2025	2024
Beginning balance	\$92,288	\$72,558
Dividend distribution of the subsidiary	(9,000)	(7,500)
Comprehensive income attributable to NCIs	14,815	18,897
Ending balance	<u>\$98,103</u>	<u>\$83,955</u>

(18) Operating revenue

	For the three-month period ended September 30,		For the nine-month period ended September 30,	
	2025	2024	2025	2024
Revenue from customer contracts				
Sales of goods	<u>\$1,888,685</u>	<u>\$1,659,030</u>	<u>\$5,108,998</u>	<u>\$5,022,500</u>

Analysis of revenue from contracts with customers for the three-month and nine-month periods ended September 30, 2025 and 2024 are as follows:

A.The Group's revenue from contracts with customers is sales of goods. The timing of revenue recognition is at a point in time.

B.Contract balances

a. Contract liabilities – current

	As of			
	30 Sep. 2025	31 Dec. 2024	30 Sep. 2024	1 Jan. 2024
Sales of goods	\$67,282	\$53,710	\$105,090	\$85,544
Customer loyalty programmes	1,433	1,619	1,576	1,810
Total	<u>\$68,715</u>	<u>\$55,329</u>	<u>\$106,666</u>	<u>\$87,354</u>

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

The changes in the Group's balances of contract liabilities for the nine-month periods ended September 30, 2025 are as follows:

	Sales of goods	Customer loyalty programs
The opening balance transferred to revenue	\$(52,103)	\$(1,619)
Increase in receipts in advance during the period (excluding the amount incurred and transferred to revenue during the period)	65,675	1,433

The changes in the Group's balances of contract liabilities for the nine-month periods ended September 30, 2024 are as follows:

	Sales of goods	Customer loyalty programs
The opening balance transferred to revenue	\$(78,034)	\$(1,810)
Increase in receipts in advance during the period (excluding the amount incurred and transferred to revenue during the period)	97,580	1,576

(19) Expected credit gains (losses)

	For the three-month period ended September 30,		For the nine-month period ended September 30,	
	2025	2024	2025	2024
Operating expenses – Expected credit gains (losses)				
Accounts receivable	\$(1,995)	\$(288)	\$(1,845)	\$41,568

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

A. The Group considers the grouping of trade receivables by counterparties' credit rating, by geographical region and by industry sector and its loss allowance is measured by using a provision matrix, details are as follow:

September 30, 2025

	Not past due	Past due				Total
		<=60 days	61-90 days	91-240 days	>=241 days	
Gross carrying amount	\$1,058,853	\$16,384	\$-	\$-	\$-	\$1,075,237
Loss rate	0.78%	1.00%	-%	-%	-%	
Lifetime expected credit losses	(8,281)	(164)	-	-	-	(8,445)
Carrying amount of accounts receivable	\$1,050,572	\$16,220	\$-	\$-	\$-	\$1,066,792

December 31, 2024

	Not past due	Past due				Total
		<=60 days	61-90 days	91-240 days	>=241 days	
Gross carrying amount	\$796,155	\$16,649	\$-	\$-	\$-	\$812,804
Loss rate	0.81%	1.00%	-%	-%	-%	
Lifetime expected credit losses	(6,450)	(166)	-	-	-	(6,616)
Carrying amount of accounts receivable	\$789,705	\$16,483	\$-	\$-	\$-	\$806,188

September 30, 2024

	Not past due	Past due				Total
		<=60 days	61-90 days	91-240 days	>=241 days	
Gross carrying amount	\$773,422	\$21,004	\$-	\$-	\$-	\$794,426
Loss rate	0.85%	1.00%	-%	-%	-%	
Lifetime expected credit losses	(6,568)	(210)	-	-	-	(6,778)
Carrying amount of accounts receivable	\$766,854	\$20,794	\$-	\$-	\$-	\$787,648

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

B.The movement in the provision for impairment of accounts receivable for the nine-month periods ended September 30, 2025 and 2024 are as follows:

	<u>Accounts receivable</u>
As of January 1, 2025	\$6,616
Addition (reversal)	1,845
Effect of EX rate	<u>(16)</u>
As of September 30, 2025	<u>\$8,445</u>
As of January 1, 2024	\$48,340
Addition (reversal)	(41,568)
Effect of EX rate	<u>6</u>
As of September 30, 2024	<u>\$6,778</u>

(20) Leases

A.Group as a lessee

The Group leases buildings. The lease terms range from 1 to 10 years. The Group may not allow to lend, sublease, sell without obtaining the consent from the lessors.

The effect of leases on the Group's consolidated financial position, financial performance and cash flows are as follow:

a.Amounts recognized in the consolidated balance sheet

I.Right-of-use assets

	<u>Land</u>	<u>Buildings</u>	<u>Total</u>
<u>Cost:</u>			
As of 1/1/2025	\$274,647	\$182,035	\$456,682
Addition	-	33,580	33,580
Disposal	-	(41,056)	(41,056)
Effect of EX rate	<u>(28,082)</u>	<u>(3,251)</u>	<u>(31,333)</u>
As of 9/30/2025	<u>\$246,565</u>	<u>\$171,308</u>	<u>\$417,873</u>

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

	Land	Buildings	Total
As of 1/1/2024	\$-	\$512,585	\$512,585
Addition	274,435	33,786	308,221
Disposal/amendment	-	(364,402)	(364,402)
Effect of EX rate	-	2,225	2,225
As of 9/30/2024	<u>\$274,435</u>	<u>\$184,194</u>	<u>\$458,629</u>

Depreciation and impairment:

As of 1/1/2025	\$4,391	\$81,417	\$85,808
Depreciation	4,129	28,719	32,848
Impairment loss	-	-	-
Disposal	-	(34,043)	(34,043)
Effect of EX rate	(637)	(1,326)	(1,963)
As of 9/30/2025	<u>\$7,883</u>	<u>\$74,767</u>	<u>\$82,650</u>

As of 1/1/2024	\$-	\$245,965	\$245,965
Depreciation	2,914	53,921	56,835
Impairment loss	-	-	-
Disposal/amendment	-	(221,597)	(221,597)
Effect of EX rate	11	957	968
As of 9/30/2024	<u>\$2,925</u>	<u>\$79,246</u>	<u>\$82,171</u>

Net carrying amount:

As of 9/30/2025	<u>\$238,682</u>	<u>\$96,541</u>	<u>\$335,223</u>
As of 12/31/2024	<u>\$270,256</u>	<u>\$100,618</u>	<u>\$370,874</u>
As of 9/30/2024	<u>\$271,510</u>	<u>\$104,948</u>	<u>\$376,458</u>

II. Lease liabilities

	As of		
	30 Sep. 2025	31 Dec. 2024	30 Sep. 2024
Lease liabilities	<u>\$101,127</u>	<u>\$105,119</u>	<u>\$109,806</u>
Current	<u>\$34,731</u>	<u>\$31,533</u>	<u>\$32,736</u>
Non-current	<u>\$66,396</u>	<u>\$73,586</u>	<u>\$77,070</u>

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Please refer to Note 6(22) (d) for the interest on lease liabilities recognized for the three-month and nine-month periods ended September 30, 2025 and 2024, and refer to Note 12(5) Liquidity Risk Management for the maturity analysis for lease liabilities as of September 30, 2025, December 31, 2024 and September 30, 2024.

b. Income and costs relating to leasing activities

	For the three-month period ended September 30,		For the nine-month period ended September 30,	
	2025	2024	2025	2024
The expense relating to short-term leases	\$(6,939)	\$(3,500)	\$(15,341)	\$(12,054)
The expense relating to leases of low-value assets	979	(467)	(587)	(1,877)
Income from subleasing right-of-use assets	62	-	130	241

As of September 30, 2025, and 2024, the portfolio of short-term leases of the Group to which it is committed at the end of the reporting period is dissimilar to the portfolio of short-term leases to which the short-term lease expense disclosed above and the amount of its lease commitments is NT\$0.

c. Cash outflow relating to leasing activities

	For the nine-month period ended September 30,	
	2025	2024
Cash outflow for leases	\$44,937	\$69,800

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(21) Summary statement of employee benefits, depreciation and amortization by function is as follows:

Function Nature	For the three-month period ended September 30,					
	2025			2024		
	Operating Costs	Operating expenses	Total	Operating Costs	Operating expenses	Total
Employee benefit expense						
Salaries	\$275,201	\$208,778	\$483,979	\$251,142	\$202,525	\$453,667
Labor and health insurance	21,978	10,909	32,887	22,262	10,540	32,802
Pension	7,998	7,130	15,128	7,330	6,636	13,966
Other employee benefit expense	16,059	10,809	26,868	14,772	10,063	24,835
Depreciation	160,293	26,126	186,419	145,405	22,082	167,487
Amortization	8	6,006	6,014	(32)	5,001	4,969

Function Nature	For the nine-month period ended September 30,					
	2025			2024		
	Operating Costs	Operating expenses	Total	Operating Costs	Operating expenses	Total
Employee benefit expense						
Salaries	\$800,544	\$617,650	\$1,418,194	\$766,430	\$620,971	\$1,387,401
Labor and health insurance	72,439	32,485	104,924	66,270	30,404	96,674
Pension	23,214	20,923	44,137	21,820	19,895	41,715
Other employee benefit expense	41,210	29,507	70,717	40,316	30,796	71,112
Depreciation	465,004	74,026	539,030	477,567	65,189	542,756
Amortization	29	17,217	17,246	94	13,022	13,116

According to the Article of Incorporation, not lower than 10% of profit of the current year is distributable as employees' compensation and no higher than 1% of profit of the current year is distributable as remuneration to directors and supervisors. However, the Group's accumulated losses shall have been covered.

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

The Company may, by a resolution adopted by a majority vote at a meeting of Board of Directors attended by two-thirds of the total number of directors, have the profit distributable as employees' compensation in the form of shares or in cash; and in addition thereto a report of such distribution is submitted to the shareholders' meeting. According to the amended Articles of Incorporation approved through the shareholders' meeting held on May 21, 2025, not lower than 25% of employee remuneration shall be allocated to grassroots employees. Information on the Board of Directors' resolution regarding the employees' compensation and remuneration to directors and supervisors can be obtained from the "Market Observation Post System" on the website of the TWSE.

Based on profit, the Company estimated the amounts of the employees' compensation and remuneration to directors for the three-month periods ended September 30, 2025 and 2024 amounted to NT\$62,692 thousand, NT\$5,452 thousand, and NT\$65,210 thousand, NT\$5,671 thousand respectively; the employees' compensation and remuneration to directors for the nine-month periods ended September 30, 2025 and 2024 amounted to NT\$183,594 thousand, NT\$15,965 thousand, and NT\$206,962 thousand, NT\$17,997 thousand, respectively, recognized as employee benefits.

For the year ended December 31, 2024, the Company distributed the employees' compensation and directors' remuneration in the amount of NT\$267,906 thousand and NT\$23,294 thousand, respectively, which were not significantly different from the amount accounted for in the financial statements.

For the year ended December 31, 2023, the Company distributed the employees' compensation and directors' remuneration in the amount of NT\$246,865 thousand and NT\$21,460 thousand, respectively, which were not significantly different from the amount accounted for in the financial statements.

(22) Non-operating incomes and expenses

A. Interest income

	For the three-month period ended September 30,		For the nine-month period ended September 30,	
	2025	2024	2025	2024
Financial assets measured at amortized cost	\$10,643	\$5,976	\$33,682	\$16,485

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

B. Other incomes

	For the three-month period ended September 30,		For the nine-month period ended September 30,	
	2025	2024	2025	2024
Rental income	\$13,784	\$10,461	\$36,744	\$20,404
Government grants income	73	78	218	238
Construction contract penalty income	-	-	108,182	-
Other income - others	2,813	1,046	14,301	7,493
Total	<u>\$16,670</u>	<u>\$11,585</u>	<u>\$159,445</u>	<u>\$28,135</u>

C. Other gains and losses

	For the three-month period ended September 30,		For the nine-month period ended September 30,	
	2025	2024	2025	2024
Gain (loss) from disposal of property, plant and equipment	\$(4,395)	\$-	\$(5,771)	\$(192)
Foreign exchange gain (loss), net	13,426	38,689	21,178	42,265
Gains (losses) on financial assets at fair value through profit or loss	3,359	7,592	11,994	24,372
Gains on lease modification	(10)	-	568	1,636
Impairment loss on non-financial assets	-	-	-	(19,242)
Other losses	(162)	(42)	(282)	(249)
Total	<u>\$12,218</u>	<u>\$46,239</u>	<u>\$27,687</u>	<u>\$48,590</u>

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

D. Finance costs

	For the three-month period ended September 30,		For the nine-month period ended September 30,	
	2025	2024	2025	2024
Interests on borrowings from bank	\$14,060	\$14,505	\$38,767	\$42,706
Interests on lease liabilities	370	396	1,135	1,585
Total	<u>\$14,430</u>	<u>\$14,901</u>	<u>\$39,902</u>	<u>\$44,291</u>

(23) Components of other comprehensive income (loss)

For the three-month period ended September 30, 2025

	Arising during the period	Reclassification during the period	Subtotal	Income tax benefit (expense)	OCI, Net of tax
May be reclassified to profit or loss in subsequent period:					
Exchange differences arising on translation of foreign operations	<u>\$15,092</u>	<u>\$-</u>	<u>\$15,092</u>	<u>\$-</u>	<u>\$15,092</u>

For the three-month period ended September 30, 2024

	Arising during the period	Reclassification during the period	Subtotal	Income tax benefit (expense)	OCI, Net of tax
May be reclassified to profit or loss in subsequent period:					
Exchange differences arising on translation of foreign operations	<u>\$9,998</u>	<u>\$-</u>	<u>\$9,998</u>	<u>\$(16)</u>	<u>\$9,982</u>

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

For the nine-month period ended September 30, 2025

	Arising during the period	Reclassification during the period	Subtotal	Income tax benefit (expense)	OCI, Net of tax
May be reclassified to profit or loss in subsequent period:					
Exchange differences arising on translation of foreign operations	<u>\$(88,237)</u>	<u>\$-</u>	<u>\$(88,237)</u>	<u>\$97</u>	<u>\$(88,140)</u>

For the nine-month period ended September 30, 2024

	Arising during the period	Reclassification during the period	Subtotal	Income tax benefit (expense)	OCI, Net of tax
May be reclassified to profit or loss in subsequent period:					
Exchange differences arising on translation of foreign operations	<u>\$15,967</u>	<u>\$-</u>	<u>\$15,967</u>	<u>\$(58)</u>	<u>\$15,909</u>

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(24) Income tax

A.The major components of income tax expense (income) are as follows:

Income tax expense (benefit) recognized in profit or loss

	For the three-month period ended September 30,		For the nine-month period ended September 30,	
	2025	2024	2025	2024
Current income tax expense (income):				
Current income tax expense	\$99,624	\$75,596	\$249,207	\$241,001
Adjustments in respect of current income tax of prior periods	113	(627)	(12,856)	(1,068)
Deferred tax expense (income):				
Deferred tax expense (income) relating to origination and reversal of temporary differences	2,985	(552)	18,067	(29,934)
Total income tax expense (income)	<u>\$102,722</u>	<u>\$74,417</u>	<u>\$254,418</u>	<u>\$209,999</u>

B.The assessment of income tax return

	<u>The assessment of income tax return</u>
The Company	Assessed and approved up to 2022.
Subsidiary - BeautyTech Platform Corporation	Assessed and approved up to 2023.
Subsidiary - Mayin Investment Co., Ltd.	Assessed and approved up to 2023.
Subsidiary - FacialBeau International Corporation	Assessed and approved up to 2023.
Subsidiary - FORIMART Corporation	It was established in 2024 no assessment has been approved.

(25) Earnings per share

Basic earnings per share is calculated by dividing net profit for the year attributable to the common shareholders of the parent entity by the weighted average number of common stocks outstanding during the year.

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Diluted earnings per share are calculated by dividing the net profit attributable to ordinary equity holders of the parent entity (after adjusting any influences) by the weighted average number of common stocks outstanding during the year plus the weighted average number of common stocks that would be issued on conversion of all the dilutive potential common stocks into common stocks.

A. Basic earnings per share

	For the three-month period ended September 30,		For the nine-month period ended September 30,	
	2025	2024	2025	2024
Net income available to common shareholders of the parent	\$396,729	\$437,770	\$1,199,379	\$1,422,282
Weighted average number of common stocks outstanding (in thousand shares)	78,000	78,000	78,000	78,000
Basic earnings per share (in NT\$)	\$5.09	\$5.61	\$15.38	\$18.23

B. Diluted earnings per share

	For the three-month period ended September 30,		For the nine-month period ended September 30,	
	2025	2024	2025	2024
Net income available to common shareholders of the parent	\$396,729	\$437,770	\$1,199,379	\$1,422,282
Net income available to common shareholders of the parent after dilution	\$396,729	\$437,770	\$1,199,379	\$1,422,282

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

	For the three-month period ended September 30,		For the nine-month period ended September 30,	
	2025	2024	2025	2024
Weighted average number of common stocks outstanding (in thousand shares)	78,000	78,000	78,000	78,000
Effect of dilution:				
Employee bonus (compensation) - stock (in thousand shares)	575	461	694	529
Weighted average number of common stocks outstanding after dilution (in thousand shares)	78,575	78,461	78,694	78,529
Diluted earnings per share (in NT\$)	\$5.05	\$5.58	\$15.24	\$18.11

No other transactions that would significantly change the outstanding common stocks or potential common stocks incurred during the period subsequent to reporting date and up to the approval date of financial statements.

7. RELATED PARTY TRANSACTIONS

(1) Deal with related parties as of the end of the reporting period

Related parties and Relationship

Related parties	Relation
Pegatron Corporation	Ultimate parent company
Kinsus Interconnect Technology Corp.	Parent company
Pegatron Japan Inc.	Other related party
Pegatron Czech S.R.O.	Other related party
Kinsus Interconnect Technology Suzhou Corp.	Other related party

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(2) Significant transactions with related parties

A. Sales

Related parties	For the three-month period ended September 30,		For the nine-month period ended September 30,	
	2025	2024	2025	2024
Kinsus Interconnect Technology Corp.	\$-	\$53	\$21	\$119
Pegatron Corporation	5	2	15	37
Kinsus Interconnect Technology Suzhou Corp.	-	387	-	387
Total	\$5	\$442	\$36	\$543

Selling prices is set by the fixed price for sale to other customers and taking into account the cost of its after-sales services plus reasonable profit. Collection terms for related parties were 90 days after monthly closing and 30 days after monthly closing.

B. Purchases

Related parties	For the three-month period ended September 30,		For the nine-month period ended September 30,	
	2025	2024	2025	2024
Pegatron Corporation	\$-	\$-	\$940	\$-

The Group purchases goods from related parties at price negotiated by both parties with reference to prevailing market rates. The payment terms for such transactions are comparable to those offered to unrelated suppliers, 90 days after monthly closing.

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

C. Lease-related parties

a. Interest expenses (Deposit included in interest computation)

Related parties	For the three-month period ended September 30,		For the nine -month period ended September 30,	
	2025	2024	2025	2024
Pegatron Corporation	\$13	\$20	\$39	\$469

b. Lease payment (Rental expense)

Related parties	Nature	For the three-month period ended September 30,		For the nine-month period ended September 30,	
		2025	2024	2025	2024
Pegatron Corporation	Buildings	\$-	\$-	\$-	\$34

c. Rent income

Related parties	Duration	Lease	Method of collection	For the three-month period ended September 30,		For the nine-month period ended September 30,	
				2025	2024	2025	2024
Pegatron Corporation	2024.04.01~ 2026.03.31	Buildings	Redeemed on the 10th of each month	\$7,161	\$8,480	\$21,482	\$16,956

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

D. Operating expense

Related parties	Nature	For the three-month period ended September 30,		For the nine-month period ended September 30,	
		2025	2024	2025	2024
Pegatron Corporation	Pay utilities	\$6,286	\$-	\$14,224	\$45,497
Pegatron Corporation	Provide services	\$-	\$-	\$5	\$-
Pegatron Japan Inc.	Provide services	\$18	\$19	\$57	\$57
Pegatron Czech S.R.O.	Provide services	\$40	\$42	\$123	\$137

E. Other revenue

Related parties	Nature	For the three-month period ended Sep. 30,		For the nine-month period ended Sep. 30,	
		2025	2024	2025	2024
Pegatron Corporation	Pay maintenance fee	\$25	\$-	\$75	\$-

F. Other receivables

Related parties	As of		
	30 Sep. 2025	31 Dec. 2024	30 Sep. 2024
Pegatron Corporation	\$4,762	\$7,107	\$6,975

G. Contract liabilities

Related parties	As of		
	30 Sep. 2025	31 Dec. 2024	30 Sep. 2024
Kinsus Interconnect Technology Corp.	\$82	\$104	\$104

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

H. Other payables

Related parties	As of		
	30 Sep. 2025	31 Dec. 2024	30 Sep. 2024
Pegatron Corporation	\$-	\$7,406	\$125
Pegatron Czech S.R.O	14	14	14
Total	<u>\$14</u>	<u>\$7,420</u>	<u>\$139</u>

I. Deposit deposit

Related parties	As of		
	30 Sep. 2025	31 Dec. 2024	30 Sep. 2024
Pegatron Corporation	<u>\$3,000</u>	<u>\$3,000</u>	<u>\$-</u>

J. On September 21, 2023 the Company's board of directors resolved to purchase Land and Buildings from the related party. Pegatron Corporation, and the total transaction amounted to NT\$3,040,000 thousand (exclude business tax). As of March 2024, Land and Buildings transfer have been completed.

K. Salaries and rewards to key management of the group.

	For the three-month period ended September, 30		For the nine-month period ended September, 30	
	2025	2024	2025	2024
Short-term employee benefits and post-employment benefits	<u>\$12,566</u>	<u>\$13,965</u>	<u>\$36,831</u>	<u>\$39,067</u>

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

8.ASSETS PLEDGED AS COLLATERAL

The following table lists assets of the Group pledged as collateral:

Item	Carrying Amount As of			Secured liabilities
	30 Sep.2025	31 Dec.2024	30 Sep.2024	
Property, plant and equipment - Land	\$196,960	\$196,960	\$196,960	Secured borrowings
Property, plant and equipment - Buildings	146,659	154,090	91,849	Secured borrowings
Refundable deposits	2,000	2,000	2,000	Security deposit to custom authority
Total	<u>\$345,619</u>	<u>\$353,050</u>	<u>\$290,809</u>	

9.SIGNIFICANT CONTINGENCIES AND UNRECOGNIZED CONTRACT COMMITMENTS

As of September 30, 2025, the Group's outstanding contracts relating to significant construction in progress and purchased property, plant and equipment were as follows:

Nature of Contract	Contract Amount	Amount Paid	Amount unpaid
Buildings	\$157,771	\$47,331	\$110,439
Machinery and equipment	21,000	6,300	14,700
Total	<u>\$178,771</u>	<u>\$53,631</u>	<u>\$125,139</u>

Contract amount paid recorded above is recorded at Construction in progress and equipment awaiting inspection.

10.LOSSES DUE TO MAJOR DISASTERS

None.

11.SIGNIFICANT SUBSEQUENT EVENTS

None.

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

12.OTHERS

(1)Categories of financial instruments

Financial assets

	As of		
	30 Sep. 2025	31 Dec.2024	30 Sep. 2024
Financial assets at fair value through profit or loss:			
Mandatorily measured at fair value through profit or loss	\$922,565	\$1,121,378	\$1,578,104
Financial assets at fair value through other comprehensive income	50,880	-	-
Financial assets measured at amortized cost			
Cash and cash equivalents (exclude cash on hand)	1,648,625	1,997,295	1,605,150
Financial assets measured at amortized cost	1,826,401	1,134,932	1,005,069
Accounts receivables	1,066,792	806,188	787,648
Other receivables	36,940	21,001	30,105
Refundable deposits	49,989	49,009	49,566
Subtotal	4,628,747	4,008,425	3,477,538
Total	<u>\$5,602,192</u>	<u>\$5,129,803</u>	<u>\$5,055,642</u>

Financial liabilities

	As of		
	30 Sep. 2025	31 Dec. 2024	30 Sep. 2024
Financial liabilities at amortized cost:			
Short-term borrowings	\$880,429	\$351,503	\$668,544
Payables	2,421,958	1,882,812	2,032,803
Long-term borrowings (including current portion with maturity less than 1 year)	456,367	558,429	522,334
Lease liabilities	101,127	105,119	109,806
Total	<u>\$3,859,881</u>	<u>\$2,897,863</u>	<u>\$3,333,487</u>

(2) Financial risk management objectives and policies

The Group's principal financial risk management objective is to manage the market risk, credit risk and liquidity risk related to its operating activities. The Group identifies, measures, and manages the aforementioned risks based on its policy and risk appetite.

The Group has established appropriate policies, procedures, and internal controls for financial risk management. Before entering into significant transactions, due approval process by the Board of Directors and Audit Committee must be carried out based on related protocols and internal control procedures. The Group complies with its financial risk management policies at all times.

(3) Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of the changes in market prices. Market risk comprises currency risk, interest rate risk and other price risk (such as equity risk).

In practice, it is rarely the case that a single risk variable will change independently from other risk variables. There are usually interdependencies between risk variables. However, the sensitivity analysis disclosed below does not take into account the interdependencies between risk variables.

Foreign currency risk

The Group's exposure to foreign currency risk relates primarily to the Group's operating activities (when revenue or expense are denominated in a different currency from the Group's functional currency) and the Group's net investments in foreign operations.

The Group has certain foreign currency receivables denominated in the same foreign currency as certain foreign currency payables, therefore natural hedge is achieved. Therefore, hedge accounting is not adopted.

The foreign currency sensitivity analysis of possible change in foreign exchange rates on the Group's profit/loss and equity is performed on significant monetary items denominated in foreign currencies as of the reporting period-end. The Group's foreign currency risk is mainly related to volatility in the exchange rates of US dollars. The information of the sensitivity analyses is as follows:

When NTD appreciates/depreciates against USD by 1%, net income (loss) for the nine-month periods ended September 30, 2025 and 2024 would increase/decrease by NT\$776 thousand and decrease/increase NT\$ 1,740 thousand, respectively.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Group's exposure to interest rate risk relates primarily to the Group's investments with variable interest rates and loans with fixed and variable interest rates, which are all categorized as loans and receivables.

The interest rate sensitivity analysis is performed on items exposed to interest rate risk as of the end of the reporting period and presumed to be held for one accounting year, including investments and bank borrowing with variable interest rates. If interest rate increases/decreases by 0.1%, the net income (loss) for the nine-month periods ended September 30, 2025 and 2024 would increase / decrease by NT\$699 thousand and NT\$444 thousand, respectively.

Equity price risk

The fair value of the Group's unlisted equity securities to market price risk arising from uncertainties about future values of the investment securities. The Group's unlisted equity securities measured at fair value through other comprehensive income. The Group manages the equity price risk through diversification and placing limits on individual and total equity instruments. Reports on the equity portfolio are submitted to the Group's senior management on a regular basis. The Group's Board of Directors reviews and approves all equity investment decisions.

Please refer to Note 12(8) for sensitivity analysis information of other equity instruments or derivatives that are linked to such equity instruments whose fair value measurement is categorized under Level 3.

(4)Credit risk management

Credit risk is the risk that counterparty will not meet its obligations under a contract and result in a financial loss. The Group is exposed to credit risk from operating activities (primarily for accounts and notes receivable) and from its financing activities, including bank deposits and other financial instruments.

Credit risk is managed by each business unit subject to the Group's established policy, procedures and control relating to credit risk management. Credit risk of all customers are assessed based on a comprehensive review of the customers' financial status, credit ratings from credit institutions, past transactions, current economic conditions and the Group's internal credit ratings. The Group also employs some credit enhancement instruments (e.g. prepayment or insurance) to reduce certain customers' credit risk.

As of September 30, 2025, December 31, 2024 and September 30, 2024, receivables from the top ten customers were accounted for 86.35%, 84.97% and 79.86% of the Group's total accounts receivable, respectively. The concentration of credit risk is relatively insignificant for the remaining receivables.

Credit risk from balances with banks, fixed-income securities and other financial instruments is managed by the Group's finance division in accordance with the Group's policy. The counterparties that the Group transacts with are determined by internal control procedures. They are banks with fine credit ratings and financial institutions, corporate and government agencies with investment-grade credit ratings. Thus, there is no significant default risk. Conclusively, there is no significant credit risk for these counter parties.

The Group adopted IFRS 9 to assess the expected credit losses. Except for contract assets and trade receivables, the remaining debt instrument investments which are not measured at fair value through profit or loss, low credit risk for these investments is a prerequisite upon acquisition and by using their credit risk as a basis for the distinction of categories.

Financial assets are written off when there is no realistic prospect of future recovery (the issuer or the debtor is in financial difficulties or bankruptcy).

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(5)Liquidity risk management

The Group maintains financial flexibility through the use of cash and cash equivalents, highly-liquid marketable securities, bank loans, etc. The table below summarizes the maturity profile of the Group's financial liabilities based on the contractual undiscounted payments and contractual maturity. The payment amount includes the contractual interest. The undiscounted interest payment relating to borrowings with variable interest rates is extrapolated based on the estimated yield curve as of the end of the reporting period.

Non-derivative financial instruments

	<u>Less than 1 year</u>	<u>1 to 2 years</u>	<u>2 to 3 years</u>	<u>3 to 4 years</u>	<u>4 to 5 years</u>	<u>>5 years</u>	<u>Total</u>
<u>As of September 30, 2025</u>							
Borrowings	\$914,998	\$63,974	\$101,304	\$96,521	\$91,740	\$163,350	\$1,431,887
Payables	2,421,958	-	-	-	-	-	2,421,958
Lease liabilities	35,910	27,172	19,875	12,387	6,458	1,928	103,730
<u>As of December 31, 2024</u>							
Borrowings	\$391,770	\$32,829	\$100,463	\$107,673	\$110,318	\$292,027	\$1,035,080
Payables	1,882,812	-	-	-	-	-	1,882,812
Lease liabilities	32,818	26,652	19,037	13,912	9,065	6,861	108,345
<u>As of September 30, 2024</u>							
Borrowings	\$703,848	\$28,429	\$80,989	\$102,192	\$101,915	\$295,053	\$1,312,426
Payables	2,032,803	-	-	-	-	-	2,032,803
Lease liabilities	34,074	27,164	19,804	13,805	9,729	8,695	113,271

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(6) Movement schedule of liabilities arising from financing activities

Movement schedule of liabilities for the nine-month periods ended September 30, 2025:

	Short-term borrowings	Long-term borrowings	Refundable deposits	Lease liabilities	Total liabilities from financing activities
As of January 1, 2025	\$351,503	\$558,429	\$3,615	\$105,119	\$1,018,666
Cash flows	528,926	(102,188)	31	(29,009)	397,760
Non-cash changes					
Lease range changes	-	-	-	25,999	25,999
Interests expense	-	126	-	1,135	1,261
Currency rate change	-	-	-	(2,117)	(2,117)
As of September 30, 2025	<u>\$880,429</u>	<u>\$456,367</u>	<u>\$3,646</u>	<u>\$101,127</u>	<u>\$1,441,569</u>

Movement schedule of liabilities for the nine-month periods ended September 30, 2024:

	Short-term borrowings	Long-term borrowings	Refundable deposits	Lease liabilities	Total liabilities from financing activities
As of January 1, 2024	\$908,620	\$381,496	\$1,004	\$273,320	\$1,564,440
Cash flows	(240,076)	140,677	2,396	(55,869)	(152,872)
Non-cash changes					
Lease range changes	-	-	-	(110,656)	(110,656)
Interests expense	-	161	-	1,585	1,746
Currency rate change	-	-	-	1,426	1,426
As of September 30, 2024	<u>\$668,544</u>	<u>\$522,334</u>	<u>\$3,400</u>	<u>\$109,806</u>	<u>\$1,304,084</u>

(7) Fair values of financial instruments

A. The evaluation methods and assumptions applied in determining the fair value

Fair value is the price that would be received to sell a financial asset or paid to transfer a financial liability in an orderly transaction between willing market participants (not under coercion or liquidation). The following methods and assumptions are used by the Group in estimating the fair values of financial assets and liabilities:

- a. The carrying amount of cash and cash equivalents, receivables, payables and other current liabilities approximate their fair value due to their short maturity.
- b. For financial assets and liabilities traded in an active market with standard terms and conditions, their fair value is determined based on market quotation price (including listed equity securities and bonds).
- c. Fair value of equity instruments without market quotations, bank borrowing and other non-current liabilities are determined based on the counterparty prices or valuation method (including private placement of listed equity securities, unquoted public Group and private Group equity securities) are estimated using the market method valuation techniques based on parameters such as prices based on market transactions of equity instruments of identical or comparable entities and other relevant information (for example, inputs such as discount for lack of marketability, P/E ratio of similar entities and Price-Book ratio of similar entities).

B. Fair value of financial instruments measured at amortized cost

The carrying amount of the Group's financial assets and liabilities measure at amortized cost approximates their fair value.

C. Fair value measurement hierarchy for financial instruments

Please refer to Note 12(8) for fair value measurement hierarchy for financial instruments of the Group.

(8)Fair value measurement hierarchy

A.Fair value measurement hierarchy

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, based on the lowest level input that is significant to the fair value measurement as a whole. Level 1, 2 and 3 inputs are described as follows:

Level 1 – Quoted (unadjusted) market prices in active markets for identical assets or liabilities that the entity can access at the measurement date

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3 – Unobservable inputs for the asset or liability

For assets and liabilities that are recognized in the financial statements on a recurring basis, the Group determines whether transfers have occurred between Levels in the hierarchy by re-assessing categorization at the end of each reporting period.

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

B. Fair value measurement hierarchy of the Group's assets and liabilities

The Group does not have assets that are measured at fair value on a non-recurring basis. Fair value measurement hierarchy of the Group's assets and liabilities measured at fair value on a recurring basis is as follows:

As of September 30, 2025

	Level 1	Level 2	Level 3	Total
<u>Financial assets:</u>				
Financial assets at fair value through profit or loss				
Money market fund	\$922,565	\$-	\$-	\$922,565
Financial assets at fair value through other comprehensive income				
Equity instrument measured at fair value through other comprehensive income	\$-	\$-	\$50,880	\$50,880

Financial liabilities:

None

As of December 31, 2024

	Level 1	Level 2	Level 3	Total
<u>Financial assets:</u>				
Financial assets at fair value through profit or loss				
Money market fund	\$1,121,378	\$-	\$-	\$1,121,378

Financial liabilities:

None

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

As of September 30, 2024

	Level 1	Level 2	Level 3	Total
<u>Financial assets:</u>				
Financial assets at fair value through profit or loss				
Money market fund	\$1,578,104	\$-	\$-	\$1,578,104

Financial liabilities:

None

Transfers between Level 1 and Level 2 during the period

During the three-month periods ended September 30, 2025 and 2024, there were no transfers between Level 1 and Level 2 fair value measurements.

Reconciliation for fair value measurements in Level 3 of the fair value hierarchy for movements during the period is as follows:

	Asset
	At fair value through other comprehensive income
	Stock
Beginning balances as at January1,2025	\$-
Total gains and losses	
Amount recognized in OCI (presented in “Unrealized gains (losses) from equity instruments investments measured at fair value through other comprehensive income)	-
Acquisition/issues	50,880
Ending balances as of September 30, 2025	\$50,880

As at 30 September 2024:None

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Information on significant unobservable inputs to valuation

Description of significant unobservable inputs to valuation of recurring fair value measurements categorized within Level 3 of the fair value hierarchy is as follows:

As of September 30, 2025

	Valuation techniques	Significant unobservable inputs	Quantitative information	Relationship between inputs and fair value	Sensitivity of the input to fair value
Financial assets at fair value through other comprehensive income					
Unlisted companies stocks	Comparable listed Company law	discount for lack of marketability	10%	The higher the discount for lack of marketability, the lower the fair value of the stocks	5% increase (decrease) in the discount for lack of marketability would result in increase (decrease) in the Group's equity by NT\$2,544 thousand

As of December 31, 2024 :None.

As of September 30, 2024: None.

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(9) Significant financial assets and liabilities denominated in foreign currencies

Information regarding the significant financial assets and liabilities denominated in foreign currencies was listed below. (In Thousands)

	As of					
	30 Sep. 2025			31 Dec. 2024		
	Foreign Currencies	Exchange Rate	NTD	Foreign Currencies	Exchange Rate	NTD
<u>Financial assets</u>						
Monetary items:						
USD	\$36,926	30.2598	\$1,117,378	\$24,743	33.0398	\$817,514
<u>Financial liabilities</u>						
Monetary items:						
USD	\$39,216	30.4710	\$1,194,955	\$19,417	32.7900	\$636,689
<u>Foreign currency resulting in exchange gain or loss</u>						
USD			\$22,974			\$8,738
Other			\$(1,796)			\$13,694

	As of		
	30 Sep. 2024		
	Foreign Currencies	Exchange Rate	NTD
<u>Financial assets</u>			
Monetary items:			
USD	\$23,752	31.5801	\$750,103
CNY	\$58,907	4.5180	\$266,149
<u>Financial liabilities</u>			
Monetary items:			
USD	\$29,187	31.6600	\$924,075
CNY	\$26,083	4.5180	\$117,844

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Foreign currency resulting in exchange gain or loss

USD	<u>\$14,329</u>
CNY	<u>\$10,252</u>
Other	<u>\$17,684</u>

(10)Capital management

The primary objective of the Group's capital management is to ensure that it maintains a strong credit rating and healthy capital ratios in order to support its business and maximize shareholder value. The Group manages and adjusts its capital structure in light of changes in economic conditions. To maintain or adjust the capital structure, the Group may adjust dividend payment to shareholders, return capital to shareholders or issue new shares.

13.ADDITIONAL DISCLOSURES

(1)Information on significant transactions

A.Financing provided to others: None.

B.Endorsement/Guarantee provided to others: None.

C.Marketable securities held as of September 30, 2025 (excluding investments in subsidiaries, associates and joint ventures): Please refer to attachment 1.

E.Related party transactions with purchase or sales amount of at least NT\$100 million or 20 percent of the paid-in capital for the nine-month period ended September 30, 2025: Please refer to attachment 2.

F.Receivables from related parties of at least NT\$100 million or 20 percent of the paid-in capital as of September 30, 2025: Please refer to attachment 3.

G.Inter Group relationships and significant inter Group transactions for the nine-month period ended September 30, 2025: Please refer to attachment 7.

(2) Information on investees

A. Name, locations and related information of investees as of September 30, 2025 (excluding investees in Mainland China): Please refer to attachment 4.

B. Investees over which the Group exercises control shall be disclosed of information under Note 13(1):

a. Financing provided to others: None.

b. Endorsement/Guarantee provided to others: None.

c. Material marketable securities held as of September 30, 2025 (excluding investments in subsidiaries, associates, and joint ventures): Please refer to attachment 5.

d. Related party transactions with purchase or sales amount of at least NT\$100 million or 20 percent of the paid-in capital for the nine-month period ended September 30, 2025: Please refer to attachment 6.

e. Receivables from related parties of at least NT\$100 million or 20 percent of the paid-in capital as of September 30, 2025: None.

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

(3)Information on investments in Mainland China:

A.Name of investee in China, main business, paid-in capital, method of investment, investment flows, percentage of ownership, investment gain or loss, carrying amount at the end of reporting period, inward remittance of earning or loss and the upper limit on investment in China:

(In Thousands of New Taiwan Dollars/ In Thousands of foreign currency)

Name of Investee in China	Main Business	Paid-in Capital	Method of Investment (Note 1)	Accumulated Outflow of Investment from Taiwan as of January 1, 2025	Investment Flows		Accumulated Outflow of Investment from Taiwan as of September 30, 2025	Profit/ Loss of Investee	Percentage of Ownership (Direct or Indirect Investment)	Share of Profit/Loss	Carrying Amount as of September 30, 2025	Accumulated Inward Remittance of Earnings as of September 30, 2025	Accumulated Outflow of Investment from Taiwan to Mainland China as of September 30, 2025	Investment Amounts Authorized by Investment Commission, MOEA	Upper Limit on Investment in China by Investment Commission, MOEA
					Outflow	Inflow									
Pegavision (Jiangsu) Limited	Producing and selling medical equipment	\$194,610 (USD 6,500)	(1)	\$150,150	\$44,460	\$-	\$194,610	\$(24,436) (Note 7 and 8)	100%	\$(24,436) (Note 7, 8 and 9)	\$126,471 (Note 7, 8 and 9)	\$-	\$194,610	\$194,610	\$6,792,001

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

BeautyTech Platform (Shanghai) Corporation	Selling medical equipment and cosmetic products	\$127,444 (USD 4,100)	(3) (Note 2)	\$14,885	(Note 5)	\$-	\$109,928	\$8,592 (Note 7 and 8)	85%	\$7,303 (Note 7, 8 and 9)	\$153,131 (Note 7, 8 and 9)	\$-	\$109,928	\$109,928	\$308,897
Pegavision (Shanghai) Limited	Selling medical equipment	(Note 5)	(3) (Note 3)	\$95,043	\$-	(Note 5)	\$-	\$(887) (Note 7 and 8)	85%	\$(754) (Note 7, 8 and 9)	\$-	\$-			
Gemvision Technology (Zhejiang) Limited	Selling medical equipment and cosmetic products	\$99,222 (RMB 22,000) (Note 7)	(3) (Note 4)	\$-	\$-	\$-	\$-	\$(894) (Note 7 and 8)	85%	\$(760) (Note 7, 8 and 9)	\$107,671 (Note 7, 8 and 9)	\$-			

Note 1: The investment methods are divided into the following three types, just indicate the types:

- (1) Go directly to the mainland China for investment.
- (2) Reinvest in mainland China through a third-region company.
- (3) Other methods.

Pegavision Corporation and Subsidiaries

Notes to Consolidated Financial Statements (Continued)

(Amounts Expressed in Thousands of New Taiwan Dollars unless Otherwise Specified)

Note 2: 100% Shares of BeautyTech Platform (Shanghai) Corporation owned and directly invested by BeautyTech Platform Corporation.

Note 3: To improve the synergy of the Group, the equity of Pegavision (Shanghai) Limited was transferred to BeautyTech Platform Corporation from the Company.

Note 4: 100% Shares of Gemvision Technology (Zhejiang) Limited owned and directly invested by Pegavision (Shanghai) Limited.

Note 5: As part of the Group's business reorganization, BeautyTech Platform (Shanghai) Corporation has merged with Pegavision (Shanghai) Limited in 2025. BeautyTech Platform (Shanghai) Corporation is the surviving entity, and Pegavision (Shanghai) Limited was dissolved upon the completion of the merger.

Note 6: As of September 30, 2025, the following investments in investee companies in Mainland China had not yet been remitted:

(a) FacialBeau (Jiangsu) Corporation which is 100% held by FacialBeau International Corporation was registered on February 25, 2022.

(b) Pegavision (Shanghai) Limited which is 100% held by the Company was registered on April 23, 2024.

Note 7: Amounts in foreign currencies are translated into New Taiwan dollars using the exchange rates on the balance sheet date.

Note 8: Gain/loss on investment is recognized based on the reviewed financial statements of the parent company's Auditors in Taiwan.

Note 9: Transaction between consolidated entities are eliminated in the consolidated financial statements.

B. Significant transactions with investees in China:

- a. Purchase and balances of related accounts payable as of September 30, 2025: None.
- b. Sale and balance of related accounts receivable as of September 30, 2025: Please refer to attachment 7.
- c. Property transaction amounts and resulting gain or loss: None.
- d. Ending balance of endorsements/guarantees or collateral provided and the purposes: None.
- e. Maximum balance, ending balance, interest rate range and total interest for current period from financing provided to others: None.
- f. Transactions that have significant impact on profit or loss of current period or the financial position, such as services provided or rendered: Please refer to attachment 7.
- g. Above transactions are eliminated upon preparation of consolidated financial statements. Please refer to attachment 7 for details.

14. SEGMENT INFORMATION

The major operating revenues of the Group come from selling contact lenses. The chief operating decision maker reviewed the overall operating results to make decision about resources to be allocated to and evaluated the overall performance.

Pegavision Corporation and Subsidiaries

Marketable Securities Held as of September 30, 2025 (excluding investments in subsidiaries, associates and joint ventures)

Attachment 1

(In Thousands of New Taiwan Dollars)

Name of Held Company	Type and Name of Marketable Securities	Relationship with the Issuer	Financial Statement Account	As of September 30, 2025			Fair Value	Note
				Shares / Units	Carrying Amount	Shareholding %		
Pegavision Corporation	Money market funds:							
	Yuanta Wan-Tai Money Market Fund	-	Financial assets at fair value through profit or loss	366,690	\$5,753	-	\$5,846	
	Yuanta De-Li Money Market Fund	-	Financial assets at fair value through profit or loss	14,919,989	252,122	-	256,451	
	Mega Diamond Money Market Fund	-	Financial assets at fair value through profit or loss	1,366,785	17,700	-	18,081	
	FSITC Taiwan Money Market Fund	-	Financial assets at fair value through profit or loss	32,196,204	519,531	-	519,932	
	Add: Valuation Adjustment				5,204			
	Total				<u>\$800,310</u>		<u>\$800,310</u>	
	Stocks :		Financial assets at fair value through other comprehensive					
	Azalea Vision BV	-	income or loss	171,428	<u>\$50,880</u>	7.79%	<u>\$50,880</u>	

Pegavision Corporation and Subsidiaries

Related Party Transactions with Purchase or Sales Amount of At least NT\$100 Million or 20% of the Paid-in Capital

For the nine-month periods ended September 30, 2025

Attachment 2

(In Thousands of New Taiwan Dollars)

Company Name	Related Party	Nature of Relationship	Transaction Details				Abnormal Transaction		Notes/ Accounts Payable or Receivable		Note
			Purchase/ Sale	Amount	% to Total	Payment/ Collection Term	Unit Price	Payment/ Collection Term	Ending Balance	% to Total	
Pegavision Corporation	Pegavision Japan Inc.	Subsidiary	Sales	\$2,917,840	66.74%	90 days after monthly closing	Similar to those to third party customers.	T/T to 90 days after monthly closing	Accounts receivable \$808,493	66.03%	Note
Pegavision Corporation	BeautyTech Platform Corporation	Subsidiary	Sales	265,532	6.07%	Within 120 days after monthly closing	Similar to those to third party customers.	T/T to 90 days after monthly closing	Accounts receivable 121,641	9.93%	Note

Note: Transactions are eliminated when preparing the consolidated financial statements.

Pegavision Corporation and Subsidiaries

Receivables from Related Parties of at Least NT\$ 100 Million or 20% of the Paid-in Capital

As of September 30, 2025

Attachment 3

(In Thousands of New Taiwan Dollars)

Company Name	Related Party	Nature of Relationship	Ending Balance	Turnover Ratio	Overdue		Amount Received in Subsequent Periods	Loss allowance
					Amount	Action Taken		
Pegavision Corporation	Pegavision Japan Inc.	Subsidiary	\$808,493 (Note)	5.23	\$-	-	\$303,611	\$-
Pegavision Corporation	BeautyTech Platform Corporation	Subsidiary	\$121,641 (Note)	2.77	\$-	-	\$38,421	\$-

Note : Transactions are eliminated when preparing the consolidated financial statements.

Pegavision Corporation and Subsidiaries
Name, locations and related information (Excluding Investees in Mainland China)
As of September 30, 2025

Attachment 4

(In Thousands of Foreign Currency / New Taiwan Dollars)

Investor	Investee	Business Location	Main Business and Product	Original Investment Amount		Balance as of September 30, 2025			Net Income (Loss) of the Investee	Share of Income (Loss) of the Investee	Note
				As of September 30, 2025	As of December 31, 2024	Shares	%	Carrying Value			
Pegavision Corporation	Pagavision Japan Inc.	Japan	Selling medical equipment	JPY 9,900	JPY 9,900	198 shares	100.00%	\$209,319	\$48,868	\$48,868	Note 1
Pegavision Corporation	Mayin Investment Co. , Ltd.	Taiwan	Investing activities	NTD 246,003	NTD 246,003	32,277,000 shares	100.00%	\$687,657	\$96,469	\$96,469	Note 1
Pegavision Corporation	PEGAVISION VIETNAM COMPANY LIMITED	Vietnam	Selling and producing medical equipment	NTD 631,333	NTD 631,333	-	100.00%	\$554,694	\$(10,047)	\$(10,047)	Note 1
Pegavision Corporation	Zhuhe Investment Co., Ltd.	Taiwan	Investing activities	NTD 20,000	NTD 20,000	2,000,000 shares	10.00%	\$19,531	\$(2,073)	\$(220)	
Pegavision Corporation	PEGAVISION NETHERLANDS B.V.	Netherlands	Selling medical equipment	EUR 1,150	-	-	100.00%	\$38,190	\$(2,836)	\$(2,836)	Note 1
Mayin Investment Co. , Ltd.	BeautyTech Platform Corporation	Taiwan	Selling medical equipment and cosmetic products	NTD 107,500	NTD 107,500	8,500,000 shares	85.00%	\$437,604	\$112,298	\$95,453	Note 1
Mayin Investment Co. , Ltd.	FacialBeau International Corporation	Taiwan	Selling medical equipment and cosmetic products	NTD 27,500	NTD 27,500	2,750,000 shares	55.00%	\$25,142	\$904	\$497	Note 1
BeautyTech Platform Corporation	Beautytech Platform (Singapore) Pte. Ltd.	Singapore	Selling medical equipment and cosmetic products	-	USD 200	-	-	\$-	\$(313)	\$(313)	Note 1.2
BeautyTech Platform Corporation	FORIMART Corporation	Taiwan	Selling medical equipment and cosmetic products	NTD 15,000	NTD 15,000	1,500,000 shares	100.00%	\$15,109	\$59	\$59	Note 1
BeautyTech Platform Corporation	BEAUTYTECH PLATFORM (VIETNAM) LIMITED LIABILITY COMPANY	Vietnam	Selling medical equipment and cosmetic products	NTD 6,923	NTD 6,923	-	70.00%	\$3,741	\$(3,627)	\$(2,539)	Note 1
FacialBeau International Corporation	Aquamax Vision Corporation	USA	Selling medical equipment and cosmetic products	USD 1,100	USD 1,100	11,000,000 shares	100.00%	\$6,337	\$(543)	\$(543)	Note 1
FacialBeau International Corporation	RODNA Co., Ltd.	Korea	Selling medical equipment and cosmetic products	KRW 100,000	KRW 100,000	-	100.00%	\$1,823	\$(65)	\$(65)	Note 1
FacialBeau International Corporation	IKIDO Inc.	Japan	Selling medical equipment and cosmetic products	JPY 9,900	JPY 9,900	198 shares	100.00%	\$1,884	\$(42)	\$(42)	Note 1

Note 1 : Transactions are eliminated when preparing the consolidated financial statements.

Note 2 : BEAUTYTECH PLATFORM (SINGAPORE) PTE. LTD. has completed the cancellation of registration in 2025 due to group business adjustments.

Pegavision Corporation and Subsidiaries

Marketable Securities Held as of September 30, 2025 (excluding investments in subsidiaries, associates and joint ventures)

Attachment 5

(In Thousands of New Taiwan Dollars)

Name of Held Company	Type and Name of Marketable Securities	Relationship with the Issuer	Financial Statement Account	As of September 30, 2025			Fair Value	Note
				Shares / Units	Carrying Amount	Shareholding %		
Mayin Investment Co. , Ltd. BeautyTech Platform Corporation	Money market funds:							
	FSITC Taiwan Money Market Fund	-	Financial assets at fair value through profit or loss	970,261	\$15,565	-	\$15,668	
	Yuanta De-Li Money Market Fund	-	Financial assets at fair value through profit or loss	502,952	8,360	-	8,645	
	Yuanta Wan-Tai Money Market Fund	-	Financial assets at fair value through profit or loss	2,221,592	34,235	-	35,420	
	FSITC Taiwan Money Market Fund	-	Financial assets at fair value through profit or loss	3,871,598	62,278	-	62,522	
	Add: Valuation Adjustment				1,817			
	Total				<u>\$122,255</u>		<u>\$122,255</u>	

Pegavision Corporation and Subsidiaries

Related Party Transactions with Purchase or Sales Amount of At least NT\$100 Million or 20% of the Paid-in Capital

For the nine-month periods ended September 30, 2025

Attachment 6

(In Thousands of New Taiwan Dollars)

Company Name	Related Party	Nature of Relationship	Transaction Details				Abnormal Transaction		Notes/Accounts Payable or Receivable		Note
			Purchase/ Sale	Amount	% to Total	Payment/ Collection Term	Unit Price	Payment/ Collection Term	Ending Balance	% to Total	
Pegavision Japan Inc.	Pegavision Corporation	Subsidiary	Purchase	\$2,917,840	100.00%	90 days after monthly closing	No suppliers to be compared with	No suppliers to be compared with	Accounts payable \$808,493	100.00%	Note
BeautyTech Platform Corporation	Pegavision Corporation	Subsidiary	Purchase	\$265,532	91.09%	Within 120 days after monthly closing	No suppliers to be compared with	No suppliers to be compared with	Accounts payable \$121,641	95.86%	Note

Note : Transactions are eliminated when preparing the consolidated financial statements.

Pegavision Corporation and Subsidiaries
Intercompany Relationships and Significant Intercompany Transactions for the nine-month periods ended September 30, 2025

Attachment 7

(In Thousands of New Taiwan Dollars)

No. (Note 1)	Company Name	Counter-Party	Nature of Relationship (Note 2)	Intercompany Transaction			
				Financial Statement Account	Amount	Terms	Percentage to Consolidated Net Revenue or Total Assets (Note 3)
	<u>2025.01.01~2025.09.30</u>						
0	Pegavision Corporation	Pegavision Japan Inc.	1	Sales revenue	\$2,917,840	90 days after monthly closing	57.11%
0	Pegavision Corporation	Pegavision Japan Inc.	1	Accounts receivable	808,493	90 days after monthly closing	5.07%
0	Pegavision Corporation	Pegavision (Vietnam) Company Limited	1	Other revenue	11,165	90 days after monthly closing	0.22%
0	Pegavision Corporation	Pegavision (Vietnam) Company Limited	1	Accounts receivable	8,193	90 days after monthly closing	0.05%
0	Pegavision Corporation	Pegavision (Vietnam) Company Limited	1	Other receivable	10,141	90 days after monthly closing	0.06%
0	Pegavision Corporation	Gemvision Technology (Jiangsu) Limited	1	Sales revenue	22,266	Within 180 days after monthly closing	0.44%
0	Pegavision Corporation	Gemvision Technology (Jiangsu) Limited	1	Accounts receivable	17,413	Within 180 days after monthly closing	0.11%
0	Pegavision Corporation	Gemvision Technology (Jiangsu) Limited	1	Operating expense	11,141	Within 180 days after monthly closing	0.22%
0	Pegavision Corporation	BeautyTech Platform Corporation	1	Sales revenue	265,532	Within 120 days after monthly closing	5.20%
0	Pegavision Corporation	BeautyTech Platform Corporation	1	Accounts receivable	121,641	Within 120 days after monthly closing	0.76%
0	Pegavision Corporation	BeautyTech Platform Corporation	1	Operating expense	58,516	Within 120 days after monthly closing	1.15%
0	Pegavision Corporation	BeautyTech Platform Corporation	1	Other payable	6,839	Within 120 days after monthly closing	0.04%
0	Pegavision Corporation	Gemvision Technology (Zhejiang) Limited	1	Sales revenue	53,143	Within 180 days after monthly closing	1.04%
0	Pegavision Corporation	Gemvision Technology (Zhejiang) Limited	1	Contract liabilities	77,783	Within 180 days after monthly closing	0.49%
0	Pegavision Corporation	Gemvision Technology (Zhejiang) Limited	1	Accounts receivable	9,604	Within 180 days after monthly closing	0.06%
0	Pegavision Corporation	FacialBeau International Corporation	1	Sales revenue	8,889	Within 90 days after monthly closing	0.17%
0	Pegavision Corporation	PEGAVISION NETHERLANDS B.V.	1	Accounts receivable	6,582	Within 180 days after monthly closing	0.04%
1	FacialBeau International Corporation	BeautyTech Platform Corporation	3	Sales revenue	10,122	Within 30 days after monthly closing	0.20%
1	FacialBeau International Corporation	BeautyTech Platform Corporation	3	Other operating revenue	10,157	Within 30 days after monthly closing	0.20%
1	FacialBeau International Corporation	BeautyTech Platform Corporation	3	Other revenue	18,800	Within 30 days after monthly closing	0.37%
2	Mayin Investment Co., Ltd.	BeautyTech Platform Corporation	3	Lease revenue	9,007	Within 30 days after monthly closing	0.18%
3	BeautyTech Platform (Shanghai) Corporation	Gemvision Technology (Zhejiang) Limited	3	Service revenue	39,364	30 days after monthly closing	0.77%

Note 1: Transaction information between Parent company and its subsidiaries should be disclosed by codes below:

(1) Parent company is coded "0".

(2) The subsidiaries are coded from "1" in the order presented in the table above.

Note 2: Relationship are divided into the following three types and the types are required to be indicated:

(1) From the parent company to a subsidiary.

(2) From a subsidiary to the parent company.

(3) Between subsidiaries.

Note 3: Regarding the percentage of transaction amount to consolidated operating revenues or total assets, it is computed based on the ending balance to consolidated total assets for balance sheet items; and based on interim accumulated amount to consolidated net revenue for income statement items.

Note 4: Amounts in foregin currencies are translated into New Taiwan dollars using the exchange rates on the balance sheet date.

Note 5: Transactions exceeding NT\$5,000 thousand have been disclosed.